Podcasts about epidiolex

What, you may ask, is TSC. When I first met our guest, Kari Luther Rosbeck, I had the same question. TSC stands for tuberous sclerosis complex. As soon as Kari defined the term for me it struck a nerve close to home for me. My great nephew actually has tuberous sclerosis complex and was first diagnosed with this rare disease when he was but a child. My conversation with Kari was far reaching and quite educational for me as I suspect it will be for you.   TSC affects some fifty-thousands persons in this country and about 1 million around the world. The TSC alliance, founded in 1974, has worked to promote support, research and the dissemination of information about this rare disease.   Kari has been the CEO for many years. She began with the organization in 2001. While her main interest growing up was in being an actress as she says, “living in New York City means that you work while developing an acting career”. In Kari's case, she found another interest which was fundraising and being involved in the nonprofit world.   My conversation with Kari is quite enjoyable and, as I said, quite educational. I am sure you will find much invaluable information in this episode. At the end of our time together Kari will tell us all how we can become involved and help the TCS Alliance. I hope you will find ways to support this effort as what the organization does goes far beyond what you might think.       About the Guest:   Kari Luther Rosbeck, President and CEO, TSC Alliance Kari has made it her life mission to use her 35 years of nonprofit and volunteer management experience to help create a future where everyone with TSC has what they need to live their fullest lives.  She has served as President and CEO since November 2007 and previously held progressive leadership positions with the organization since 2001. Kari is responsible for the overall management and administration of the organization including strategic planning, implementation of organizational strategies and evaluation of results to ensure the TSC Alliance meets its mission. During her tenure, the TSC Alliance established a comprehensive research platform fostering collaboration with industry and academia to move treatments for TSC forward in a more expedited way. Because of her leadership, the organization has taken an active role in educating the TSC community about clinical trials to diminish the time for recruitment, including pivotal trials that have led to three FDA-approved drugs specifically for TSC. In 2019, the organization launched a Research Business Plan with the goal to change the course of TSC for those living with it today and for generations to come paired with an aggressive fundraising campaign leading to more than $16 million raised. Since joining the TSC Alliance, the organization has grown from a $2.1 million annual operating budget to $10 million in 2022 and is heralded with top ratings by watchdog organizations. Kari graduated with a BA degree in Theatre from the State University of New York at Albany and upon graduation founded a theatre company with fellow graduates in New York, NY.  After the loss of her first child, Noell, to sudden infant death, she dedicated her career to helping other families. Kari is the proud mother of Trent, Bradey, Wynter and Rhys and grateful to her husband Chris for his unending support. When not working, she enjoys traveling, playing golf and being an avid Minnesota Vikings fan. Read Kari's Profile in Success.   Ways to connect with Kari:   Facebook: https://www.facebook.com/tscalliance; @krosbeck Instagram: https://www.instagram.com/tscalliance; @karirosbeck LinkedIn: https://www.linkedin.com/company/697362/admin/; @kari-luther-rosbeck-ba24805/ X: https://twitter.com/tscalliance; @KariRosbeck Threads: https://www.threads.net/@tscalliance Website: www.tscalliance.org     About the Host:   Michael Hingson is a New York Times best-selling author, international lecturer, and Chief Vision Officer for accessiBe. Michael, blind since birth, survived the 9/11 attacks with the help of his guide dog Roselle. This story is the subject of his best-selling book, Thunder Dog.   Michael gives over 100 presentations around the world each year speaking to influential groups such as Exxon Mobile, AT&T, Federal Express, Scripps College, Rutgers University, Children's Hospital, and the American Red Cross just to name a few. He is Ambassador for the National Braille Literacy Campaign for the National Federation of the Blind and also serves as Ambassador for the American Humane Association's 2012 Hero Dog Awards.   https://michaelhingson.com https://www.facebook.com/michael.hingson.author.speaker/ https://twitter.com/mhingson https://www.youtube.com/user/mhingson https://www.linkedin.com/in/michaelhingson/   accessiBe Links https://accessibe.com/ https://www.youtube.com/c/accessiBe https://www.linkedin.com/company/accessibe/mycompany/   https://www.facebook.com/accessibe/       Thanks for listening!   Thanks so much for listening to our podcast! If you enjoyed this episode and think that others could benefit from listening, please share it using the social media buttons on this page. Do you have some feedback or questions about this episode? Leave a comment in the section below!   Subscribe to the podcast   If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on Apple Podcasts or Stitcher. You can subscribe in your favorite podcast app. You can also support our podcast through our tip jar https://tips.pinecast.com/jar/unstoppable-mindset .   Leave us an Apple Podcasts review   Ratings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. If you have a minute, please leave an honest review on Apple Podcasts.       Transcription Notes:   Michael Hingson ** 00:00 Access Cast and accessiBe Initiative presents Unstoppable Mindset. The podcast where inclusion, diversity and the unexpected meet. Hi, I'm Michael Hingson, Chief Vision Officer for accessiBe and the author of the number one New York Times bestselling book, Thunder dog, the story of a blind man, his guide dog and the triumph of trust. Thanks for joining me on my podcast as we explore our own blinding fears of inclusion unacceptance and our resistance to change. We will discover the idea that no matter the situation, or the people we encounter, our own fears, and prejudices often are our strongest barriers to moving forward. The unstoppable mindset podcast is sponsored by accessiBe, that's a c c e s s i capital B e. Visit www.accessibe.com to learn how you can make your website accessible for persons with disabilities. And to help make the internet fully inclusive by the year 2025. Glad you dropped by we're happy to meet you and to have you here with us. . Well, welcome once again to another episode of unstoppable mindset where inclusion, diversity and the unexpected meet, and I bet we get to do a bunch of all of that today. Our guest is Kari Luther rosbeck, and Kari and I met through Sheldon Lewis from accessibe. Sheldon is great at finding folks for us to get to chat with. And when I started learning about Kari, one of the things that I kept reading was a term TSC, and I didn't know what TSC was. So when Kari and I first met, I asked her about TSC, and she said it stands for tubular sclerosis complex, which immediately struck a nerve with me, because I have a great nephew who has tubular sclerosis. And as it turns out, his parents have actually and had actually attended an event where Kari was and then just this past March or April or whenever, and you can correct me, Kari, but they went to another event, and my other niece and nephew, Tracy and Charlie, attended, as I just told, Kari, I'm very jealous they didn't let me come along, but that's okay. I stayed home and slept. But anyway, Kari, I want to welcome you to unstoppable mindset. It's really great that you're here, and I want to thank you for taking the time to be with us. It   Kari Luther Rosbeck ** 02:42 is such an honor. Michael and I love talking with your family, and it was so wonderful to have them with us at comedy for a cure this year. Well, it   Michael Hingson ** 02:53 it was really fun to hear about the event from them, and I'm glad that that they all enjoyed it. And of course, Nick is is a person who deserves all the attention and help all of us can give. He's had tubular sclerosis, been diagnosed with it for quite a while, and is actually, I think, beating some odds, because some people said, Oh, he's not going to last very long, and he's continuing to do well. And just don't ever get him into a conversation about sports and the Dodgers, because he's a Dodger fan, okay,   03:24 as he should be. By the conversation.   Michael Hingson ** 03:28 Well, he is a Dodger fan as he should be. I just want to point that out, yes, yes, for those of us here. Well, Nick, Nick probably   Kari Luther Rosbeck ** 03:36 was, well, when Nick was diagnosed, we had a very different prognosis for TSC back then.   Michael Hingson ** 03:45 Well, yeah, I know, and it's like everything with medicine, we're making a lot of advances. We're learning a lot, and of course, we're paying a lot of attention to these different kinds of issues. I mean, even blindness, we're paying a lot of attention to blindness, and we're slowly getting people it's a very slow process, but we're slowly getting people to recognize blindness isn't the problem. It's our attitudes about blindness that are the problems. And I think that's true with most things, and I think that if people really thought about Nick and and felt, well, he can't do much because of they would recognize he can do a whole lot more than they think he can, 100% which is really important. Well, let's start a little bit about you. And why don't you tell us about the early Kari growing up and all that and how we got where we are, well, thank   Kari Luther Rosbeck ** 04:43 you for the opportunity to do that. My middle name is Lacher. That's also my maiden name. My dad and mom were in education, primarily. My dad also dabbled in some politics. We moved around. Quite a bit when I was a child, I think before seventh grade, or before I was 18, we knew 13 times so that really, you know, you become adaptable because you have to be and inclusive, because you have to be because you're in all of these new environments. From the time I was six years old, I wanted to be an actress. I wrote my own plays, I organized a neighborhood, I think, when I was seven, and we performed a play I wrote. And that's what my degree is in, in theater. And Michael, as you probably know, when I was 27 I had my first child, Noel, who unfortunately passed away from sudden infant death, and it completely changed the rest of my life. From that point forward, I really wanted to do something that impacted families, so they never had to experience the type of grief that I went through at a very somewhat young age. And then from from that point, I took all of the skills that I'd been using in the work life, not theater, because I lived in New York, and you have to work to live, so you could do theater before my then husband and I moved to Minneapolis, but I had always done fundraising. I had always done administration, so I just kind of naturally took in all of those skills, community and grassroots building. I went to work for the American Refugee Committee in Minneapolis, and then from there, worked at international service agencies, which is a workplace giving umbrella organization representing all of the premier international organizations. And my job there, as a regional director was to go into workplaces and give two or three minute presentations and convince people to give to international causes. My favorite was I was pregnant. I had a pregnancy kit, what they would give people in developing the developing world, where you would have a razor blade, a string, a plastic sheet, and that's how they delivered babies. And that was a really effective presentation, as you can imagine. I got to the TSC Alliance because my boss at international service agencies became the CEO of the TSC Alliance in early 2000s and he brought me over to start our volunteer outreach program, build our grassroots movement, and from there, I definitely got involved in fundraising. The admin side was interim CEO, and then CEO,   Michael Hingson ** 07:55 well, gee, so so many questions. Why did you guys move so many times?   Kari Luther Rosbeck ** 08:01 Well, my dad got his PhD and became dean of students at Arkadelphia State University, or Henderson State University in Arkadelphia, rather. And he did great, but he loved politics, and he had the opportunity to become the executive director of the Republican Party of Arkansas when it wasn't cool to be a Republican in Arkansas, and that really was his passion. And from there, he became a he led a congressional campaign for a candidate in Littleton, Colorado, and when that candidate didn't win, he realized that he really needed to have a more stable life for his family. So we moved to Knoxville, Illinois, and he became a vice president at a community college, and from that point forward, that was his his career. We moved to upstate New York. I'm leaving out a few moves just to make it simple. We moved to upstate New York my freshman year in college, where he became a President of Community College there, and then ultimately, he ended back in his hometown, in Mattoon, Charleston, Illinois, where he led the local community college until he retired, and the Student Union at Lakeland College is actually named after my   Michael Hingson ** 09:30 father. Wow. So is he still with us today? He is not.   Kari Luther Rosbeck ** 09:34 He passed away from idiopathic pulmonary fibrosis in 2017   Michael Hingson ** 09:38 Well, that's no fun. How about your mom? She is, she   Kari Luther Rosbeck ** 09:43 still lives in that soon. Yep, she is the matriarch of our family. That's for sure.   Michael Hingson ** 09:50 A lot of moves. Needless to say, I wonder what your father would say about politics today, it started to be different in 2016 and. 2017 but I wonder what he would think about politics in general. Today, I   Kari Luther Rosbeck ** 10:04 am not sure. I have wondered that question a lot. The one thing my dad was always great at, though, was the ability to see balanced viewpoints, and it's something I always loved and respected about my father, and   Michael Hingson ** 10:19 I think that's important. I think people really need to do more of that. And we just, we're not, we're not seeing that, which is really scary. We're not seeing it on so many levels, not just politics. But, you know, we don't get into politics much on unstoppable mindset, because, as I love to tell people, if we do that, I'm an equal opportunity abuser anyway, and and I, and I'm with Mark Twain. Congress is that grand old benevolent asylum for the helpless. So you know?   Kari Luther Rosbeck ** 10:48 Well, I will say this. My dad taught me how to be an advocate from a very young age. Yeah, what it means to not be afraid to use your voice. That's the best thing we can get out of politics, that using your voice for the greater good is one of the most important things that you can do. The   Michael Hingson ** 11:10 thing that I think people are forgetting today is they love to use their voice, but they don't love to use their ears. Yes, which is another thing, but I I hear what you're saying. I joined the National Federation of the Blind, which is the largest blindest consumer organization in the country, and I joined in 1972 when I was a senior in college, and learn from experts about being an advocate. And I think it's really important that we have advocacy. And the value of really good advocates is that they are able to look at all sides of an issue and really make intelligent decisions and also recognize when it's time to maybe change as things evolve in terms of views. And we just don't see any of that today. People say I'm an advocate. Yeah, well, without thinking about it, and without really looking at the options, and without looking at stands, it's just amazing how people, as I said, use their voices, but not their ears today. I agree. Yeah, it's, it's, it's a tough world, and it's, it's a challenge. I read an article about a year ago in the New York Times all about how we're losing the art of real conversation, which is why this podcast is so much fun, because we do get to converse.   Kari Luther Rosbeck ** 12:36 That's right, I I'm so excited to be with you today.   Michael Hingson ** 12:40 Well, so you got into nonprofit, in a sense, pretty early, and you've certainly been involved at reasonable levels for now, 23 years after September 11, I worked at Guide Dogs for the Blind for six and a half years, as well as being a public speaker. But loved working in the nonprofit sector, although I had a lot of fun with some of the nonprofit people, because what I would constantly advocate, if you will, is that development in the nonprofit world is really just no different than sales. Instead of selling and making a profit, in a sense, you're selling to secure donations, but it's still sales. And people would say, Oh no, it's totally different, because nonprofit is just totally different than what you do if you're working with a company and selling for a company. And I'm going, I'm not sure it's that different.   Kari Luther Rosbeck ** 13:40 Well, what I think is that you're selling hope and right? It's all about relationships. But unlike widgets, we have a lot of different programs that have created such progress, hope and support for the tuberous sclerosis complex community. And I really enjoy talking about what those programs help make possible for people like your great nephew, Nick well   Michael Hingson ** 14:12 and and it's important to do that. I The only thing I would say on selling widgets, as opposed to hope, is if you talk to Steve Jobs or Bill Gates, they would say that widgets very well could also be a mechanism to to move toward hope and dreams. And so again, I think it's just, it's it's all using the same techniques, but different things. I tell people now that as a keynote speaker, I think it's a whole lot more fun to sell life and hope and dreams than it is to sell computer hardware.   Kari Luther Rosbeck ** 14:54 But you're right about computer hardware, and for instance, wearables that are. Really making a difference in some of the breakthroughs that we see today. So under percent correct.   Michael Hingson ** 15:05 Well, tell us a little bit about the whole tubular sclerosis complex Alliance, the TSC Alliance, and you got started in it. And what was it like, if you will, back in the day, and it's not a great term, I'm telling you, I I'd love to to have fun with that, but what it used to be like, and what it is now, and what's happening, sure.   Kari Luther Rosbeck ** 15:27 So when I started June 18, 2001 nearly 23 years ago, the organization had about seven employees. Today, we have 23 we in those days, we knew what the genes were in TSC, and soon after I came to work, we discovered how the TSC genes impact the underlying genetic pathway. That was awesome, because that led to some key clinical trials and ultimately an approved drug. What I say about the early days is we were we did a beautiful job of holding people's hands, offering them support, but there were no medications that really directly impacted TSC that were FDA approved,   Michael Hingson ** 16:21 maybe it would help if we actually define what TSC is. Yes, of   Kari Luther Rosbeck ** 16:25 course, let's start with that. Tuberous sclerosis complex is a rare genetic disorder that causes tumors to grow throughout the body, the brain, heart, kidney, liver, lungs. It is the leading genetic cause of epilepsy and one of the leading causes of autism. Epilepsy impacts about 85% of people with TSC autism, about 50% one in 6000 life first will have TSC. TSC impacts about 50,000 Americans and a million people worldwide, and it's variable. No two people are exactly the same, not even identical twins. So people can have mild cognitive impact. They might have moderate or severe. People can have mild cognitive impact, but at some point in their life, perhaps needing a lung transplant. TSC is progressive. So for women of childbearing age, lymph angiolio, myomatosis, or Lam can impact the lungs. We can see kidney growth of tumors in the kidneys that can impact quality of life. So it's variable, and some of our adults live independently. Others require more complex care. It's usually diagnosed in childhood and in infancy, either in utero, where you can see two or more heart tumors in a regular ultrasound. Sometimes you're diagnosed after birth, when a baby begins having seizures. Some people aren't diagnosed till they're teenagers with the appearance of angiofibromas or skin tumors on their face. And occasionally, people are diagnosed when they're adults. They have kids of their own, their children are diagnosed with TSC, and then they are subsequently diagnosed with TSC. So it runs the gamut.   Michael Hingson ** 18:31 So it is something that very much is or can be genetic. It is genetic.   Kari Luther Rosbeck ** 18:38 Yes, it's caused by mutations in one of two genes, TSC one or TSC two, on the ninth or 16th chromosome that controls cell growth and proliferation, which is why you see the appearance of non malignant tumors. And that is what impacts all the organ systems. Yeah,   Michael Hingson ** 19:00 and it is not a fun thing, needless to say, to be around or to have, and it's not something that we have control over. Nick, I know does live with his parents. I don't know whether Nick will ever be able to live independently. He does have seizures and sometimes, and it's not predictable, although he's doing a little bit better job of controlling them with medication, but he'll probably always live with someone. But what a wonderful person to have around. Yes,   Kari Luther Rosbeck ** 19:35 he is definitely enjoyable. And that's, I mean, that's the thing about TSC. We have we have independent adults. We have kids, we have semi dependent adults. We have dependent adults. The one thing about our community and our organization is this is a home for everybody.   Michael Hingson ** 19:58 So when did the. See Alliance actually first begin   Kari Luther Rosbeck ** 20:01 1974 so it started with four moms around a kitchen table in Southern California, and two of those four moms are still in touch with the TSC Alliance. I talked to two of our Founding Moms quite frequently. They are very inspirational. They had this tremendous foresight to think about what the community needed or what they would need in the future. So our organization, the TSC Alliance, we actually have a new vision statement as of this year. So our vision statement is the TSC Alliance wants to create a future where everyone affected by TSC can live their fullest lives, and our mission statement is to improve quality of life for everyone affected by tuberous sclerosis complex by catalyzing new treatments, driving research toward a cure and expanding access to lifelong support. What so some of the ways that that we do this, as you know, is to fund and drive research, to empower and support our community, to raise awareness of TSC, because we want to provide the tools and resources and support for those living with TSC, both individuals and caregivers. We want to make sure that as an organization, we are pushing research forward by a research platform that we've helped create through the years, and we want to make sure that people are diagnosed early and receive appropriate care. So it's really important to us to raise awareness in the general public, but also among the professional community.   Michael Hingson ** 21:52 So this is the 50th anniversary of the TSC Alliance. Yes, it is. And I would dare say, based on what you're talking about, there's a lot to celebrate.   Kari Luther Rosbeck ** 22:04 We have so much to celebrate. Michael, there's been so many accomplishments over the years, from the creation of our professional advisory board early on that provided guidance to the organization to today, we have three FDA approved drugs specifically to treat TSC as an organization in 2006 we started the very first natural history database anywhere in the world that still exists today, with over 2700 participants, and that allows us to really understand how TSC progresses through a lifetime, and then we, as an organization, in partnership with a group of our TSC clinics, helped with the first preventative clinical trial for epilepsy in the United States, and that was really to look at Babies with TSC to treat them before the first seizure, to see if we can prevent or delay epilepsy.   Michael Hingson ** 23:07 So So tell me a little bit about the the three different drugs that are available. What? What do they do? Without getting too technical, how do they work, and so on, because, obviously, the tumors are there. And so what do the drugs do to address all of that   Kari Luther Rosbeck ** 23:24 great question, the first approved drug for TSC everolimus is an mTOR inhibitor, mammalian target of rapamycin. So if you remember I talked about the two TSC genes working as a complex to control the genetic underlying genetic pathway. Well, that underlying genetic pathway is mTOR, and there happened to be a class of drugs that was developed to help with organ transplant and anti rejection. Ever roll. This is a synthetic of rapamycin that was found on rap a rap the islands, rap immune island. So what that particular drug has been approved for, and how it works in TSC is to shrink certain types of brain tumors to shrink tumors in the kidneys, and it's also used as adaptive therapy for seizures associated with TSD. So what we know is it is extremely effective, but if you go off the medication, the tumors will grow back. So it's not a cure, but it's moving in the right direction, right second drug that was approved is the first FDA cannabinoid drug, Epidiolex, and that treats seizures associated with TSC. The third approved drug is a topical rapamy. So it treats those skin tumors on the face. I   Michael Hingson ** 25:04 don't know. It's really interesting. Medical science comes up with all these terms that are tongue twisters. How do they do that? You're 100% correct. Oh, it's a fun world. What's on the horizon, what kinds of things are coming that will kind of either enhance what they do or other sorts of medications? Yeah,   Kari Luther Rosbeck ** 25:28 thanks for asking that. So I think for us, in 2019 we put together a really aggressive research, research business plan, and our goal with this was to ultimately the vision change the course of TSC, and so we have a research platform that really helps accelerate drug development. So we fund research grants or young investigators to keep them interested in the field and to generate new ideas. We have a pre clinical consortium where we work with a contract research organization. We've licensed different mouse models that can try drugs for both epilepsy and tumor growth and behaviors, and so that is really built a pipeline of new potential therapies for TSC we also have this clinical research consortium that we work with. We have 74 TSC clinics across the country, of which 17 are centers of excellence, and we're working with our TSC clinics and centers of excellence to when drugs come out of the pre clinical or when companies come to us and they want to institute clinical trials, we will work with them to be in touch with our clinics, to educate our community about what clinical trials are out there, so they know what questions to ask or how to appropriately weigh risk benefit, so that's a really important part of our platform. We also, I mentioned earlier, a natural history database to help us understand how TSC progresses through a lifetime, but also a bio sample repository, so we'll understand why TSC is so different person to person. So with all of those tools working together, what we want to do is ultimately determine how to predict an individual's risk for the many manifestations of TSC so if we knew who was at risk, say, for epilepsy, and we could intervene to delay or prevent epilepsy. Could we do the same with kidney tumors? So that's what I mean about predicting and prevention. We would like to develop biomarkers to help accelerate outcome measures and clinical trials. We would love to have an intervention early on. Remember, I said that we helped start the first preventative clinical trial for epilepsy. You need an intervention to get on the newborn screening panel. If we could be on the newborn screening panel and identify babies early, that is the greatest way to change the course of the disease. Of course, we obviously want to test more compounds in our pre clinical consortium to make sure that we are building that pipeline for new and better drugs in the future, and we definitely want to develop patient reported outcomes. So how does this disease impact quality of life for individuals and families living with it, so that we'll know in the future, if there are different potential treatments, does it impact or improve their quality of life? And the FDA looks at patient reported outcomes quite seriously, so we want to build that for future clinical trials and clinical studies. Finally, one of the biggest unmet needs in TSC is what we call TSC associated neuropsychiatric disorders, or taint This is an umbrella term for brain dysfunction that includes everything from sleep problems to depression, anxiety, aggressive behavior, executive functioning, how people learn. So it is definitely an umbrella term, and almost everybody is impacted by tanned in some way that are living with TSC. So we want to better understand who might be at risk for which parts of tan so that we can intervene and improve quality of life.   Michael Hingson ** 29:55 Something that comes to mind we hear people talking. Think a fair amount today about gene therapy and how all of that might work to cure various diseases and so on. Is there room for that in Tse, since especially it's caused by two specific genes?   Kari Luther Rosbeck ** 30:14 Great question. We actually are working with some gene therapy companies in our pre clinical consortium looking to see if we can intervene that way.   Michael Hingson ** 30:26 It's a few years off, yeah, I can imagine, but it would be an interest if, if it truly can be done, since you're clearly able to tell that there are specific genes that are that are causing this. It's an interesting concept, given the state of science today, to think about whether that could lead to, even if it's not immediate, but later, cures for TSC and other such things, and   Kari Luther Rosbeck ** 30:57 we might start with organ specific gene therapy. For instance, if we had gene therapy early on in the brain, again, thinking about preventing seizures from ever developing, if we were able to implement gene therapy in the kidneys so or lungs so women never develop lamb, that would be a huge breakthrough. Yeah. So thinking about how that might work and how that could impact our community is tremendous,   Michael Hingson ** 31:28 I would think so. And I would think if they are able to do some work in that regard, it would be very revolutionary. And obviously, the more we learn about gene therapy overall, the more it will help with what medical science can do for TSC as well. That's right. So what does the Alliance do for families and individuals? What kinds of specific things do you all do?   Kari Luther Rosbeck ** 31:57 Yeah, we have   32:00 developed 14   Kari Luther Rosbeck ** 32:01 community regions across the country where we work with our volunteers. So they'll in their regions, host community educational meetings, walks, where they bring the community together, which is hugely important offer peer to peer support. So that is on a regional level. On our team, we have support navigators, so people that are available to take calls, emails, texts to really help when people either receive a new diagnosis, will spend a lot of time making sure they get to the right clinics, resources, support systems, or when a new manifestation arises, or if people are having some access to medication or access to care issues, we have a TSC navigator so that is a proactive online tool that people can log into and that will really take them through the journey in a way they want to gain information. So it's really written in in small bites, so that if people want more information, they can dive deeper. That's hugely important for individuals impacted. We have regular webinars, regional conferences, and every four years we hold a World Conference. Well, we will bring in experts from all over the world to cover the many manifestations of TSC so people are informed to make the best decisions for them and their families. They'll also talk about new clinical trials or new research on the horizon, or they're talk about social service tools that are really important for living or guardianship or financial planning, so those things that aren't just medical, but really impact people's lives.   Michael Hingson ** 33:57 So today, what, what do you think? Or how would you describe, sort of the social attitude toward TSC and people with TSC, or is it, is it more manifested in Well, this guy has seizures and so on, so TSC doesn't directly tend to be the thing that society views.   Kari Luther Rosbeck ** 34:22 That's a great question. And because TSC is so variable, I'm going to say to you, it's different person to person. One of the things we did a few years ago was create these little business cards that described what TSC was. So if somebody's out at a restaurant, they might hand it to their waiter or waitress to say, We want you to know that our for instance, our child has TSC and so you understand what you might see as you wait on us. For example, I still think that for those that are more severely in. Acted. I talked about tanned and some folks with more severe behaviors. You know, our society, it's attitude, right? You talked about that in your presentation of diversity to inclusion, we need to be much more understanding when a family is trying to handle a seizure or or behaviors and not pass judgment on that family, let the family handle that situation. So I would just say it's individual to individual, but one of the most amazing experiences, as is at our world conferences, where everybody can just be. And everybody understands that TSC is variable. And you might have a child over here with a seizure dog. You might have an adult group in one corner talking and dancing, but everybody comes together, yeah,   Michael Hingson ** 35:58 yeah. And that's really important to do, and that's you raise a really good point. Obviously, dogs are learning to be better at seizure detection. And I was going to ask about that, because I assume that that certainly can play into helping people who have seizures, who have TSC.   Kari Luther Rosbeck ** 36:18 That is absolutely correct earlier. You asked about what it was like early on, we didn't have a lot of seizure dogs at our early conferences. That's something that really has been happening after, say, 2010 we've definitely seen a lot more seizure dogs be trained and really be helpful to families.   Michael Hingson ** 36:39 Yeah, well, and we have come so far in terms of training dogs to be able to detect seizures and detect so many things. One of my favorite stories, and it's not a seizure detection as such, but one of my favorite stories, is about a Portuguese water dog who was a show dog, but he or she, rather, was also trained to do cancer detection. And the owner, who was very competitive in doing show dog type things, as well as had started a company or a facility to deal with cancer detection, took his dog to the show, to a dog show. And every time the dog got near this one judge, it just laid down. It would not perform, it would not work. And so needless to say, this national champion didn't do very well at that show. And the guy couldn't figure out why. And he got home, and he suddenly realized, oh my gosh, I had taught the dog to lay down whenever it detected cancer, because you don't want to do something dramatic, right? And so he called the woman who was the judge, and he said, Do you have cancer? And she says, No, I don't have anything like that. Then he said, Well, you might go check that out, because and he told her, this was like a Monday when he called her, and Friday she called him back, and she said, I took your advice. And it turns out I have early stage breast cancer. We caught it in time, and it's all because of your dog.   Kari Luther Rosbeck ** 38:04 Oh my gosh, Michael, what an amazing story   Michael Hingson ** 38:10 it is. You know, we we really underestimate our dogs. I know that the first diabetic dog was a dog who who kind of learned it on his own. His person had occasional insulin reactions, and the dog became agitated. And finally, the guy realized, oh my gosh, this dog knows what I'm going to have an insulin reaction. And that led to dogs for diabetics, which is another, of course, sort of same thing that the dogs really can learn to do so many things today.   Kari Luther Rosbeck ** 38:44 Yes, yes, they can.   Michael Hingson ** 38:48 So there's always room for dogs. So we talked, I think, in sort of terms, about your the the whole research platform that you all have developed tell us more about the research platform and what it is and where it's going.   Kari Luther Rosbeck ** 39:06 Well, I definitely talked about all of the tools within our research platform. I think we're certainly taking a deeper dive into all of the tools that that we've developed, when we think about, for instance, our bio sample repository, one of the things we're doing right now is whole genome sequencing. Why? Because we're hoping with whole genome sequencing, we'll understand if there are modifier genes. Are there other things at work that makes some people more severe than other others, and then ultimately, what we'd love to learn is what medications might work best on each individual or personalized medicine, so often in TSC with seizure medications, people end up on a cocktail. We would rather avoid that, right? Wouldn't it be nice to get the medication right the first time? That's really what we are hoping for with our clinical research consortium. Right now, we're doing a couple of quality improvement studies, so one of them is around suit up or sudden, unexpected death from epilepsy, and really understanding the conversations that happen between a physician and a patient or a caregiver, and why aren't those conversations happening in TSC or when are they happening? Because we want to create change so that parents know the risks, or individuals understand the risks, and can they change their behavior to mitigate some of those risks? The other thing that we are doing is we started a reproductive perinatal Health Initiative. This came out of our 2002 world conference because we heard from a bunch of adults that this was a gap for TSC. So TSC is variable. We have some independent adults that may want to start a family someday, but we have no no consensus guide guidance, to guide them in making those decisions. So we put together a group of experts in maternal fetal health, pulmonary nephrology, imaging genetics, to come together to first talk about what are risk stratifications, both for women that are may experiences complications in pregnancy. What are those? What's a risk stratification for each individual? Also, how do we handle perinatal health? How do we care for fetuses of women with TSC, or fetuses where they have been diagnosed with TSC, and what are those recommendations and steps? So that's a real focus for us at our organization, really filling the gaps where those exist. So that's a couple of the things that that I would mention.   Michael Hingson ** 42:16 An interesting question that comes to mind, do you see prejudices or misconceptions that cause difficulties within medical science. And I ask that because I know from a blindness standpoint, so often, when a person goes into an ophthalmologist because they're having eye problems, they go in and the doctor will say, eventually after diagnosis, well, you have retinitis pigmentosa, you're going to go blind. There's nothing I can do, and literally, just walk out of the room without ever dealing with the fact that this person can still be a very normal person. Do you see any of that kind of stuff in the world of TSC so   Kari Luther Rosbeck ** 42:56 early on, less today, but we still hear about it when people are handed the diagnosis of TSC, they it could be very cold. Physicians would say, your child will never walk, they'll never talk, they'll never live a normal life. That's horrible, like you're taking away that hope. And that may not be the case for each individual with TSC, I think some of our families, when their infants begin to have a devastating type of seizure called infantile spasms that can look just like a head nod, sometimes they are misconstrued for indigestion or startle reflex, and They try to get care for their baby, they're told that they're just being paranoid and crazy. It's nothing, but the it's up to the parents right to continue to advocate, because they know something is not right and that that is the right course of action. And then for adults, I think sometimes our adults living with TSC really struggle with adequate care. We've done a really good job of pediatric care specifically for TSC, but as a country, we could do a lot more for those with developmental disabilities, including TSC and providing adequate transition from adult care, these are the places that I see prejudice or roadblocks put up for our families.   Michael Hingson ** 44:33 How do you teach or what do you do to teach parents and adults, especially about being stronger advocates.   Kari Luther Rosbeck ** 44:43 Well, first of all, we tell them to trust their instincts and trust their voice and to not give up if you're hitting a roadblock. One place call us. Maybe there are other other clinical care that we can provide for you. Yeah. If you're having an issue at work, it's really important that you get the right support to advocate for yourself, but to never, ever give up, ever give up.   Michael Hingson ** 45:11 Yeah, that's really, of course, the important part, because ultimately, and I think it's true for most all of us, we know ourselves better than anyone else. And as parents, we know our children better than anyone else, and certainly should never give up and work very hard to be strong advocates to support what their needs are and support them to grow and advance.   Kari Luther Rosbeck ** 45:36 That's exactly correct,   Michael Hingson ** 45:41 and it needs to happen a whole lot more, because all too often, I can imagine hearing people say, well, it's nothing, it's just your it's your imagination. Well, no, it's not, you know, but we see way too much of that kind of thing happening in the world. So it's great that that you're able to do so much. What about in the in the professional world, or in just dealing with people and their lives? What? What kind of things are you able to do to, let's say, help support somebody who wants to go out and get a job?   Kari Luther Rosbeck ** 46:21 Sure? We point them to local resources that might be an expert in that. We also have navigation guides that might help them, that are a supplemental resource to our TSC navigator. We have adult topic calls and adult open forums so that they might also get guidance and advice from their peers that have walked that journey. So those are some of the resources that we will help people who want to get a job   Michael Hingson ** 46:55 do Centers for Independent Living help.   Kari Luther Rosbeck ** 47:00 Are you familiar with those? No, I'm not familiar. Sorry, I'm not familiar. So the   Michael Hingson ** 47:04 CIL system is a system of independent living centers. It really started, I don't know, but I think in Berkeley, it's centers that teach and advocate for the whole concept of being able to live independently, and deals a lot with physical disabilities, and I'm not sure how much the developmental disability world interacts in the CIL it may be a lot more of a physical thing than anything else.   Kari Luther Rosbeck ** 47:32 Well, always great to have new resources that we can share with our community. It's worth   Michael Hingson ** 47:38 exploring Absolutely, because it could very well lead to something that would be helpful, not sure, but it's always worth exploring. The arc is   Kari Luther Rosbeck ** 47:47 another organization I was gonna ask about that frequently. Yes, we've, we've had a partnership with the arc in the past. Many of our community regions obviously work with local arc chapters. It is a partnership that we truly value, and they have a ton of resources that are available for individuals, seeking jobs, seeking Independent Living, seeking so or housing for families. So we don't need to replicate what somebody is already doing. Well, we will partner with that organization,   Michael Hingson ** 48:25 and that makes sense. There's no sense in replicating. It's all about collaborating, which makes a lot more sense to do. Anyway,   Kari Luther Rosbeck ** 48:33 exactly we agree.   Michael Hingson ** 48:36 Well, so what are so, what are your your sort of long term goals from here? Oh,   Kari Luther Rosbeck ** 48:45 long term goals from here? Well, we want to continue to improve quality of life for everyone. We want to make sure that there is adequate transition between childhood and adult in terms of medical care, independent living, or housing or schooling, or whatever that transition may employ, we really want to make sure that we continue the pipeline of new treatments. We want to drive towards a cure. We want to support and empower every family living with TSC. One of the things that we've really been able to do because of advocacy, is to grow the TSC research program at the Department of Defense. So this is a congressionally directed medical research program. There's been an appropriation for TSC since fiscal year, 2002 and cumulatively, 221 million has been appropriated for TSC research. We want to continue to grow that. But on a state level, we've also had some success in growing state funding for. TST clinics in particular states, and for TSC research at those institutes. So over 5.7 5 million have been advocated, have been appropriated from the states of Maryland and Missouri and Michigan and Alabama. So very excited about continuing to grow that that program, as I mentioned, I think getting on the newborn screening panel would be a game changer for TSC, complete game changer. And we want to continue to grow our advocates and grow those that are available as leaders in their communities to offer support to others.   Michael Hingson ** 50:39 So the funding comes through the Department of Defense. Why is that?   Kari Luther Rosbeck ** 50:44 It is a program that is high risk, high reward. You have to have some military relevance. So so for TSC, obviously, our connection to epilepsy and our mass models that are used for developing epilepsy medications, those mass models can also be used to look at traumatic brain injury. So that's a connection. It's high risk, high reward. So understanding the underlying biology of TSC and finding that genetic pathway that I mentioned was one of the hallmark achievements early on of this program. So it's, it's, it is so amazing. The early gene therapy work for TSC started at the TSC research program at the Department of Defense.   Michael Hingson ** 51:33 And I gather you're probably getting a lot of really good support from DOD. So   Kari Luther Rosbeck ** 51:38 it doesn't come to the TSC Alliance, we advocate to make that funding available to researchers around the country. So we think of that as part of our mission for driving research. But we don't see a dime of that. Those dollars, they all go through Fort Detrick and through the Department of the Army, right? The other cool thing, though, Michael is we nominate consumer reviewers, so people that help advocate for these funds also sometimes get a seat at the table to say what research would be meaningful for their lives as a consumer. And that is a really cool, unique thing that happens.   Michael Hingson ** 52:21 Yeah, well, and I was asking about support, I was thinking more of their they're perfectly willing and pleased to be a part of this, and are really open to helping and really contributing to the research, because I would think it would help all the way around 100%   Kari Luther Rosbeck ** 52:40 and the one thing is the TSC Alliance, the DOD and NIH. We all work together so that we're not duplicative. But we have, there was a research strategic plan that was developed out of a workshop at NIH that we all follow as kind of our guiding principle. We all do different things, and we all complement each other. So out of that NIH plan, for instance, a bio sample repository and preclinical consortium was recommended, and recommended that the TSC alliance is the patient advocacy group, be the one that started that and continues to make sure that those resources continue. That's just an example. Obviously, DOD does high risk, high reward. And NIH, you know, the prevent trial that I mentioned, the first preventative trial for epilepsy in United States, was funded by the National Institute of Neurological Disorders and Stroke. We helped educate the community so that people would want to participate.   Michael Hingson ** 53:46 Well, it's, I think, important and relevant to ask, how can people get involved? What can the rest of us all do?   Kari Luther Rosbeck ** 53:54 Oh my gosh, I'm so glad you asked. Well, please go to TSC alliance.org, learn more about the organization. Become a volunteer. Help us. Help us with our walks, help us with our conferences. You can certainly get involved. If you're an individual with TSC and you want to get connected through social media, you can go to Facebook, Instagram, LinkedIn, YouTube, even Tiktok at the SC Alliance, we have very active discussion groups Michael that offer peer to peer support. 24/7 especially on Facebook, it is a private group, and those group of individuals and families have been so supportive for anyone walking this journey, you can call us at 1-800-225-6872, if you need support, you can ask for a support navigator. If you're interested in helping us with fundraising or making a donation, you can ask for our development department. If you want to volunteer, ask for. Community programs, we want all takers, and we're always also happy to talk with any organization, any nonprofit, that's wanting to pull together their programs, seek advice or work as a partner,   Michael Hingson ** 55:15 and what's the phone number? Again? 1-800-225-6872,   Michael Hingson ** 55:24 and the website is TSC   Kari Luther Rosbeck ** 55:26 alliance.org,   Michael Hingson ** 55:29 cool. Well, I've asked lots of questions. Have I left anything out? Any other things that you think we ought to cover? I   Kari Luther Rosbeck ** 55:37 think you did a great job. I would just say if anybody wants to join us at our 50th Anniversary Gala, we'd love to have you. TSD alliance.org, backslash 50 Gala. We will be celebrating october 25 at ciprianis in New York City, and we'd love to have you with us. Ooh, that sounds like it'd be fun. I know you gotta get your family to bring you this time. Well, yeah,   Michael Hingson ** 56:07 if they're going to come, they should, should take me. I'm trying to think, I don't know whether I'll be anywhere near there at the time, but my schedule changes all the time, so it's sort of like everything else you never know. But I will keep that in mind, because it would be fun to come and get to meet you in person. I would love that. Well, I want to thank you for being here with us. This has been, needless to say, very educational and very enjoyable. And of course, as you know, I have the personal stake of a great nephew, but just being able to talk about it, to hear the progress that's being made as, I think, really crucial and really important to be able to let people be aware of and I hope that people who do hear this will get involved, will at least learn more about it. Have you written any books or anything? I have   Kari Luther Rosbeck ** 56:57 not written any books. Oh, we got to get you to work. That's right, you're an inspiration.   Michael Hingson ** 57:04 Well, something to work on. You should? You should write a book about it all. That'd be a new project. It's not that you don't have enough to do, though. That's   Kari Luther Rosbeck ** 57:13 right. Michael, I'm too busy taking care of our community right now, but when I retire, that might be something I think about. Well, there   Michael Hingson ** 57:21 you go. Well, I want to thank you again for being here. This has been, I will say, enjoyable, but it's been most educational. I've learned a lot, and I appreciate your time, and I hope that, as I said, everyone else has as well. So I want to thank you for being here, and anytime in the future you want to come back and talk some more about what's going on and tell us about other new, revolutionary changes and so on. You are always welcome.   Kari Luther Rosbeck ** 57:46 Thank you. Michael, I'd love to come back. Well, thank   Michael Hingson ** 57:50 you again, and let's do it anytime you'd like, Okay, you got it.   **Michael Hingson ** 58:01 You have been listening to the Unstoppable Mindset podcast. Thanks for dropping by. I hope that you'll join us again next week, and in future weeks for upcoming episodes. To subscribe to our podcast and to learn about upcoming episodes, please visit www dot Michael hingson.com slash podcast. Michael Hingson is spelled m i c h a e l h i n g s o n. While you're on the site., please use the form there to recommend people who we ought to interview in upcoming editions of the show. And also, we ask you and urge you to invite your friends to join us in the future. If you know of any one or any organization needing a speaker for an event, please email me at speaker at Michael hingson.com. I appreciate it very much. To learn more about the concept of blinded by fear, please visit www dot Michael hingson.com forward slash blinded by fear and while you're there, feel free to pick up a copy of my free eBook entitled blinded by fear. The unstoppable mindset podcast is provided by access cast an initiative of accessiBe and is sponsored by accessiBe. Please visit www.accessibe.com . AccessiBe is spelled a c c e s s i b e. There you can learn all about how you can make your website inclusive for all persons with disabilities and how you can help make the internet fully inclusive by 2025. Thanks again for Listening. Please come back and visit us again next week.

Episode 181: Cannabinoid Hyperemesis SyndromeFuture Dr. Johnson explains the pathophysiology, assessment, and management of Cannabinoid Hyperemesis syndrome. Dr. Arreaza adds some insights on the topic.  Written by Tyler Johnson, MSIV, Western University of Health Sciences, College of Osteopathic Medicine of the Pacific-Northwest. Editing and comments by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Definition Cannabinoid hyperemesis syndrome (CHS) is a syndrome of cyclic abdominal pain, vomiting, or nausea in older adolescents and adults who have chronic ϲаnոаbis use.The term “marijuana” is considered racist by some people. In the 1930s, American politicians popularized the term “marijuana” in the U.S. to portray the drug as a “Mexican vice” and to have a justification to persecute Mexican immigrants. Epidemiology The overall prevalence of cannabinoid hyperemesis syndrome is unknown due to a lack of definitive criteria or diagnostic tests. It occurs in a population that may not disclose substance use. One study conducted in 2015 in a United States urban emergency department not named, found one-third of patients with near-daily cannabis use met criteria for having had CНЅ in the prior six months.Why are rates of CHS increasing?Between 2005-2014 hospitalizations cyclic vomiting syndromes increased by 60 %. concurrent cannabis use in hospitalized patients increasing from 2 to 21 percent. 7 years after the commercialization of cannabis in Canada, the Canadian health services found a 13-fold increase in cyclic vomiting syndromesPotential correlations for the increase in CHS are increased legalization and commercialization of cannabis, higher tetrahydrocannabinol concentrations in cannabis products, and increased recognition of the syndrome.Legal status of Cannabis in the USCannabis is legal in 24 states: Alaska, Arizona, California, Colorado, Connecticut, Delaware, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oregon, Rhode Island, Vermont, Virginia, and Washington. It is also legal in Washington, D.C. Cannabis is approved for medical use in 38 states.Federal level: Cannabis is a Schedule I drug, under the Controlled Substance Act (added in 1970) in the group of Hallucinogenic or psychedelic substances. Tetra-hydro-cannabinol (THC, a “mind-altering substance in cannabis”) is on the same list. However, cannabidiol (CBD, derived from hemp or non-hemp plants) was removed from the Controlled Substances Act in 2018. CBD is FDA-approved (under the name of Epidiolex®) to treat rare seizure disorders. CBD is still on the list of controlled substances in some states. I see THC as a problem.THC increased concentration As recreational Cannabis becomes more normalized, innovators look to find new ways to differentiate their product and increasing THC has become a common way to perform this similar to alcohol content in the beer, wine, and liquor industry. An article by Yale School of Medicine titled “Marijuana: Rising THC Concentrations in Cannabis Can Pose Health Risks” states, “In 1995, the average THC content in cannabis seized by the Drug Enforcement Administration was about 4%. By 2017, it had risen to 17% and continues to increase. Beyond the plant, a staggering array of other cannabis products with an even higher THC content like dabs, oils, and edibles are readily available—some as high as 90%.”Recently, cannabis-infused water started to be sold in some grocery stores.Pathophysiology of CHSIt is not entirely understood. Some suggest multifactorial involving cannabinoid metabolism, exposure dose and tolerance modifying receptor regulation, complex pharmacodynamics at Cannabinoid receptors, and even changes in genetics and cannabinoid variation in plants. CB1 receptors are involved in gastric secretion, sensation, motility, inflammation, and lipogenesis. The activation of CB1 and CB2 receptors has been suggested as the possible cause of CHS.Risk FactorsCHS can occur after acute or acute on chronic use but many report daily 3-5x cannabis use cannabis use over one year and many over at least two years. Median age 24 years. Interesting factsMedical visits for inhaled cannabis are more likely associated with CHS while edibles are more likely for acute psychiatric reactions.Also, CHS is a paradoxical effect since cannabis and cannabinoid receptor agonists are known antiemetics (as seen in nabilone and dronabinol (synthetic analogs of THC)) and prescribed by some physicians to combat chemotherapy effects.Clinical Features of CHSCyclical pattern with abdominal pain, severe nausea, and vomiting up to 30 episodes daily. Pain is intense and even referred to as “scromiting” due to its intense nature, causing patients to scream and vomit concurrently.Typically, it presents with 2 or more episodes over a 6-month period with no symptoms in between. It starts within 24 hours of last cannabis use (differentiating from cannabis withdrawal) and occurs at day or night. There is a gradual symptom resolution of nausea and vomiting after several days of cannabis cessation. Some patients had symptoms 2 days to 2 weeks after cessation. Diagnosis of CHSClinical diagnosisRule out neurological symptoms such as migraine headaches, acute abdomen, motion sickness, and medications, such as recent antibiotics and chemotherapy.Often the diagnosis is discovered with a thorough history reporting a decrease in symptoms with hot showers/baths.Management of CHS AcuteRehydrate with Fluids Dopamine Antagonists– Droperidol (0.625 or 1.25mg) /Haloperidol (0.05 to 0.1mg/kg with max dose of 5mg initially) favored over typical antiemetics like Zofran or Reglan.If needed, combine with an antiemetic like metoclopramide IM or ondansetron IV and consider patients' dehydration status likely requiring US-guided IV.Topical capsaicin cream 0.025 – 0.1% on the abdomen. Long term97% resolution of symptoms completely in a systematic review of patients who stopped cannabis use.Reinforce it may take several weeks of abstinence for symptoms to resolve and symptoms can worsen if cannabis is resumed. It is unknown if a reduction in use can prevent recurrence.Approaches in the clinicEducate patients on the etiology of their symptoms with complete cessation of cannabis use.Consider referral to counseling for cannabis use disorder and abstinence support for treatment-seeking cannabis users. Approach topics such as changing one's environment, seeking social support, and using self-help techniques to non-treatment-seeking individuals.Consider referring patients with polysubstance use and significant comorbidities to a supervised withdrawal management setting. Conclusion: Cannabis use is increasing with legalization and commercialization across the United States. With increased use, Cannabinoid hyperemesis syndrome incidence increases. Often it can be diagnosed with a thorough history including chronic cannabis consumption and symptomatic relief by showers. Physicians will need to develop counseling approaches to better understand CHS patients and how to approach an often-difficult topic.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Angulo MI. Cannabinoid Hyperemesis Syndrome. JAMA. 2024;332(17):1496. doi:10.1001/jama.2024.9716. Link: https://jamanetwork.com/journals/jama/fullarticle/2824833#:~:text=Cannabinoid%20hyperemesis%20syndrome%20(CHS,last%20less%20than%201%20week.Backman, Isabella, Marijuana: Rising THC Concentrations in Cannabis Can Pose Health Risks, Yale School of Medicine, August 30, 2023. https://medicine.yale.edu/news-article/not-your-grandmothers-marijuana-rising-thc-concentrations-in-cannabis-can-pose-devastating-health-risks/Buchanan, Jennie A and George Sam Wang, Cannabinoid Hyperemesis Syndrome, Up To Date, updated July 17, 2024. https://www.uptodate.com/contents/cannabinoid-hyperemesis-syndromeTheme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

Can CBD truly provide effective pain relief, or is it just another overhyped remedy? Join us in this eye-opening episode of Addiction Medicine Made Easy, where Dr. Casey Grover critically examines the realities behind cannabidiol (CBD) usage for pain management. We start the episode with inspiring encounters, including a discussion of the work of musician Matt Butler, who uses his songs to shine a light on addiction in prisons and jails. Dr. Grover also shares his heartfelt recommendation of Stephanie Wittels Wachs' book, "Everything is Wonderful and Horrible," which offers a raw perspective on coping with the loss of a loved one to overdose.As we journey deeper, we unpack a 2024 article from the Journal of Pain by Andrew Moore, which scrutinizes the effectiveness, cost, and potential harms of CBD products. Our discussion highlights the widespread use of CBD, yet flags significant issues like product purity and labeling discrepancies. The episode dives into CBD's dual roles—both as Epidiolex for seizure disorders and as a non-pharmaceutical pain relief option. Despite its popularity, current research shows mixed results on CBD's efficacy for pain relief. Furthermore, hidden risks such as the presence of THC, sedation, and hepatotoxicity are explored. This episode underscores the necessity for ongoing research and thoughtful consideration when using CBD, especially in the context of addiction treatment. Don't miss out on this thorough examination of CBD's complexities and what they mean for pain management and addiction medicine.

"Innovations in Cannabinoid Medicine: The CBDA and CBDVA Breakthrough"Today, Justin Benton discusses the benefits of cannabinoids found in the cannabis plant, particularly focusing on CBDA and the newly discovered CBDVA. He emphasizes the importance of preserving the raw form of the plant for maximum effectiveness, citing research from Dr. Raphael Mushulam. CBDVA is highlighted for its potential in treating neurological disorders such as epilepsy and autism, with comparisons made to synthetic alternatives like Epidiolex. Justin encourages listeners to explore natural, whole-plant solutions and offers access to CBDVA products for testing. Thank you for tuning in to the Miracle Plant Podcast. Remember, our mission is to heal the world with the power of this miracle plant. Join us next time for more inspiring stories and insights into the world of cannabis. Produced by PodConx 101cbd - https://101cbd.org/Email Justin Benton - jbenton@101cbd.orgGet a free consultation - askjanet.org

Dr. Ethan Russo is a board-certified neurologist, psychopharmacologist, and Founder/CEO of CReDO Science. He is an internationally recognized authority on cannabis medicine. He has authored/edited seven books and has published more than 60 peer-reviewed articles. He also holds director/advisor positions with several cannabis therapeutics companies, and he was instrumental in developing Sativex® for pain and MS, and Epidiolex® for intractable epilepsy while at GW Pharmaceuticals. At CannMed 24, Ethan will present “Cannabinoid Hyperemesis Syndrome (CHS): Unraveling the Gordian Knot”. CHS is an enigmatic condition where some chronic, heavy users of THC develop a cyclic pattern of vomiting and nausea that is only relieved by hot bathing and topical capsaicin. Ethan and his coinvestigators surveyed more than 500 cannabis users, including 205 diagnosed CHS patients, and investigated genetic mutations in 28 CHS patients and 12 controls to identify behaviors and genetic markers that could indicate CHS risk. During our conversation, we discuss:  What is CHS and who does it affect  Why cases of CHS appear to be on the rise  Possible genetic markers that could indicate CHS susceptibility     Steps cannabis users can take to prevent developing CHS  Why some people in the cannabis community don't believe CHS is a real thing and more  Thanks to This Episode's Sponsor: Cannabis Nurses Network Established in 2015, the Cannabis Nurses Network™ is a professional nursing and professional development organization for nurses around the globe. By educating nurses on the science behind the plant and providing a global nursing network, nurses are supported and empowered to implement their knowledge within their community. Learn more at cannabisnursesnetwork.com Additional Resources what-is-chs.com ethanrusso.org CReDO-science.com Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation Unraveling the Mystery of Cannabinoid Hyperemesis Syndrome - CannMed 2019 Panel Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive

Up to this point, I have resisted doing any episodes around cannabis because 1. I'm a little old-school 2. I probably don't know enough and 3. I want to avoid, in the words of my guest, “being painted with green paint” and tainting the brand.Separating emotions from logic, however, if there are cannabis components that could be effective therapies, it would be foolish to ignore them. There is already one cannabis-derived compound approved by the FDA. Epidiolex is pharmaceutical-grade cannabidiol (CBD) prescribed for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. Pebble Life Science is taking a rigorous approach to investigate whether other compounds derived from hemp might be effective as therapies, either for other neurological disorders or even cancer, initially focused on ovarian.I spoke with Patrick Moran, the founder and CEO of Pebble Life Science about their approach, the challenges they have faced, and the success they have had in forming collaborations with the MD Anderson Cancer Center as well as participating in the NCI Applicant Assistance Program.Everything we discussed is in the pre-clinical phase, preparing for and gearing up toward clinical trials. A key event in this journey was the 2018 farm bill that allows the cultivation of hemp as long as the THC content is below 0.3%. That opened the door to growing and extracting components from hemp, all non-psychotropic, for investigation.Thanks for reading cc: Life Science! Subscribe for free to receive new posts and support my work.Either way, I appreciate you spending time here.One obstacle was bridging the gap between (clinically unproven) claims of cannabis killing cancer and putting in place procedures to rigorously investigate those possibilities. Another challenge, as mentioned above, was breaking through the cloud of suspicion that exists around cannabis. After being invited to apply for a drug development grant by the Cancer Prevention and Research Institute of Texas, one reviewer labeled them as drug dealers.While the research staff took that hard, their legal team suggested taking their data and the positive feedback they had received from the other three CPRIT reviewers and contacting the NCI. That led to an NCI sponsorship for the NIH Applicant Assistant Program which Patrick said was invaluable in helping his executive team prepare to submit an SBIR grant to help fund clinical trials.Based on pre-clinical studies in mice, Pebble is currently focused on the potential of a hemp-derived compound as both an adjuvant therapy and a frontline monotherapy for ovarian cancer. At the end of our interview, I asked Patrick what he had learned that would be helpful to any biotech startup whether or not they are in the cannabis space.Interestingly, I've recently had another conversation with someone I hope will be on this podcast soon. We concluded that science is difficult. People can be more so. It's yet one more challenge to get people to change their thinking or to deal with the obstacles they place in front of you, intentionally or not. I hope this episode help you figure that out on your own journey.There were a few terms I had to look up in our conversation. You may find these useful:RPPA analysisEntourage effectYour deepest insights are your best branding. I'd love to help you share them. Chat with me about custom content for your life science brand. Or visit my website.0 Comments This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit cclifescience.substack.com

A short intro for the eminent Dr. Ethan Russo is challenging. Ethan Russo is a neurologist who explored the Amazon rain forest in the 90's to explore medicinal plants with aboriginal tribes. He returned to the USA and became interested in medicinal cannabis. He quickly became an expert in the field, and worked as a consultant for GW Pharmaceuticals. Later, as a Senior Medical Advisor for GW, he was involved with the development of Sativex and Epidiolex.Dr. Russo founded CReDO Science, who create innovative products and services related to cannabis and the endocannabinoid system. Trevor and Dr. Russo discuss Cannabinoid Hyperemesis Syndrome (CHS). It is a relatively rare, but very unpleasant condition that causes some heavy users of cannabis to be very nauseous and vomit a lot. Dr. Russo and collaborators have developed a genetic test that may be able to predict who will get CHS and thus who might want to avoid THC containing cannabis altogether.Then Trevor and Dr. Russo discuss THCV. Come hear about all the potential indications for this lesser known cannabinoid.Make sure you listen to the very, very end of this episode for a hidden my cannabis story.Ethan Russo Website - ethanrusso.orgCannabinoid Hyperemesis Syndrome Survey and Genomic Investigation - articleCHS DNA test - what-is-chs.comMusic by: Nelson Little - High Road - YouTubeAdditional Music:Desiree Dorion desireedorion.comMarc Clement - FacebookTranscripts, papers and so much more at: reefermed.ca

Jonathan Miller interviews Rayetta Henderson, Senior Managing Scientist at Tox Strategies about her research and her testimony before the House Oversight Committee on the safety of hemp-derived CBD. If you have questions about the episode or ideas for Hemp related topics, email us at hemplegallyspeaking@fbtlaw.com. Hemp Industry questions covered in the episode:  What were the results of your toxicology studies on the safety of CBD isolate? How were thise results different from the studies championed by FDA concerning pharmaceutical-grade CBD found in the prescription drug Epidiolex? Why are studies of rodents applicable to the experience of humans? Have there been enough studies of CBD for FDA or Congress to be able to establish appropriate limits if CBD in dietary supplements and food/beverage? What counsel to you give to Congress as they go about the process of drafting legislation to regulate CBD?

A short intro for the eminent Dr. Ethan Russo is challenging. Ethan Russo is a neurologist who explored the Amazon rain forest in the 90's to explore medicinal plants with aboriginal tribes. He returned to the USA and became interested in medicinal cannabis. He quickly became an expert in the field, and worked as a consultant for GW Pharmaceuticals. Later, as a Senior Medical Advisor for GW, he was involved with the development of Sativex and Epidiolex.Dr. Russo founded CReDO Science, who create innovative products and services related to cannabis and the endocannabinoid system. Trevor and Dr. Russo discuss Cannabinoid Hyperemesis Syndrome (CHS). It is a relatively rare, but very unpleasant condition that causes some heavy users of cannabis to be very nauseous and vomit a lot. Dr. Russo and collaborators have developed a genetic test that may be able to predict who will get CHS and thus who might want to avoid THC containing cannabis altogether.Then Trevor and Dr. Russo discuss THCV. Come hear about all the potential indications for this lesser known cannabinoid.Make sure you listen to the very, very end of this episode for a hidden my cannabis story.Ethan Russo Website - ethanrusso.orgCannabinoid Hyperemesis Syndrome Survey and Genomic Investigation - articleCHS DNA test - what-is-chs.comMusic by: Nelson Little - High Road - YouTubeAdditional Music:Desiree Dorion desireedorion.comMarc Clement - FacebookTranscripts, papers and so much more at: reefermed.ca

Hunter Land, PhD is the Vice President of Research & Development at Biopharmaceutical Research Company, one of the few DEA Schedule I, FDA compliant cannabinoid research and development companies. He has 20 years of R&D expertise across 25 different indications, as well as 12 years of cannabinoid-focused research.  Most notably, he was GW Pharma's first full-time R&D employee in the US, where he played a critical role in the development of Epidiolex® and Sativex®, and co-authored multiple protocols for the treatment of refractory epilepsy, multiple sclerosis, and pain. At CannMed 23, Hunter's presentation was titled Effect of Cannabinoids and Cannflavins on Neurodegeneration, Lifespan, and Healthspan, which is the basis for our conversation today. You can find a link to that video in the show description. Topics we discussed include: Defining lifespan, healthspan, and longevity Why C. elegans are good organisms for studying toxicity and longevity Whe entourage effect, more specifically whether a combination of compounds has a greater effect on longevity than single compounds How do cannabis compounds compare to other longevity drugs like metformin and resveratrol Whether cannabis compounds could be used prophylactically for conditions like Alzheimer's and dementiaDetermining the ideal dosing range for cannabinoids Whether CBD and CBG should be incorporated into a healthy lifestyle to improve longevity  Thanks to This Episode's Sponsor - Trulieve Trulieve strives to bring you the relief you need in a product you can trust. Their plants are hand-grown in a facility with a controlled environment specially designed to reduce unwanted chemicals and pests, keeping the process as natural as possible at every turn. Their mission is to provide compassionate care patients can trust when traditional medicine is not enough. Their specially-trained staff works hand-in-hand with YOUR physician to provide the right products and the correct dosage to ensure you get the compassionate care you need. To learn more visit trulieve.com Additional Resources Effect of Cannabinoids and Cannflavins on Neurodegeneration, Lifespan, and Healthspan - Hunter Land (CannMed 23 Presentation Video) Biopharmaceutical Research CompanyReview the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]

Inspiring Events, Family Video & Important Studies. *Note the CINEMAS TRIAL for Epidiolex - #S10e107 RECENT EVENTS MDBR Blog https://www.syngapresearchfund.org/post/mdbr-2023-everything-we-want-to-c-happening-for-syngap1-camaraderie-community-collaboration Paddle Slap video https://www.youtube.com/watch?v=F9SaHPzd5bU Paddle Slap blog https://www.syngapresearchfund.org/post/syngap-paddle-slap-is-a-thing Family Video and Fundraiser: Shaeffer Video https://www.youtube.com/watch?v=Z_dI059yPeM Shaeffer Fundraiser https://secure.givelively.org/donate/syngap-research-fund-incorporated/support-srf-for-story-s-19th-birthday SRF in the World: SRF in Mexico - Our Voice is Getting Louder blog Syngap.Fund/Voice SRF in Poland - https://twitter.com/beatasyngap1/status/1664996361585197057?s=20 STUDIES ENDD S1 NHS - Email ENDD@chop.edu to sign up and please cc mike@curesyngap1.org, lauren@curesyngap1.org & sydney@curesyngap1.org - https://drive.google.com/file/d/1ASUkKQOgjbs9hkJVCJ40N8MbVFH4X9_h/view# CHOP NHS ENDD Blog: https://Syngap.Fund/CHOPNHS CORNELL English https://redcap.link/syngapcaregiversurvey Spanish https://redcap.ctsc.weill.cornell.edu/redcap_protocols/surveys/?s=MWTW743PHENPPRPY COMBINEDBrain Biorepository https://www.syngapresearchfund.org/webinars/74-combinedbrain-biobank-our-partnership-with-srf-for-syngap1 STXBP1 Foundation, (July 21st-23rd 2023; 10600 Westminster Blvd, Westminster, CO 80020) Yellow Brick Road Project, (July 30th-August 2nd (Ponte Vedra Lodge & Club, 607 Ponte Vedra Blvd, Ponte Vedra Beach, FL, 32082) CINEMAS STUDY - Mild Intellectual Delay https://cinemasstudy.com/#right_for_me  PRESS Axios Fruit Flies article https://www.axios.com/local/salt-lake-city/2023/06/09/fruit-fly-medical-research-university-utah FUTURE EVENTS June 21 - Splash for Syngap https://www.syngapresearchfund.org/post/share-your-love-for-someone-with-syngap1-for-splash4syngap August 26 - Syngap Soiree  https://e.givesmart.com/events/wiH October 7 - Scramble for Syngap https://secure.givelively.org/event/syngap-research-fund-incorporated/scramble-for-syngap-2023 October 21 - SynGAP Research Fund Gala Honoring Caren Leib - https://e.givesmart.com/events/wBy/ October 30-31 - Epilepsy Awareness Day at Disneyland  https://epilepsyawarenessday.org/lobby-page/ Nov 30-Dec 1 - SYNGAP1 Conference 2023 hosted by SynGAP Research Fund https://www.syngapresearchfund.org/professionals/syngap1-roundtable-2023-syngap-research-fund Conference pre-registration link: Syngap.Fund/2023conf Book hotels ASAP: https://Syngap.Fund/2023hotel T-shirts https://www.bonfire.com/srf-syngap1-conference-2023/ WEBINARS Upcoming: June 15 - Quantifying perturbed SYNGAP1 Function Caused by Coding Mutations - Dr. Michael Courtney from Turku in Finland https://www.syngapresearchfund.org/webinars/79-quantifying-perturbed-syngap1-function-caused-by-coding-mutations - Previous: Therapeutic Strategies for Autism: Targeting Three Levels of the Central Dogma of Molecular Biology - Presented to the SYNGAP1 Community - Lilia Iakoucheva & Derek Hong https://www.syngapresearchfund.org/webinars/78-therapeutic-strategies-for-autism-targeting[…]tral-dogma-of-molecular-biology-with-a-focus-on-syngap1 PODCAST - Syngap Stories, interviews, see #10 with Dani Williams  https://www.syngapresearchfund.org/podcast-episodes/episode-010 Volunteer with SRF! Info@SyngapResearchFund.org  This is a podcast: subscribe to and rate this 10 minute #podcast #SYNGAP10 here  - https://www.syngapresearchfund.org/syngap10-podcast Apple podcasts:  https://podcasts.apple.com/us/podcast/syngap10-weekly-10-minute-updates-on-syngap1-video/id1560389818 Episode 107 of #Syngap10 - June 14, 2023 #epilepsy #autism #intellectualdisability #id #anxiety #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology #GeneChat --- Send in a voice message: https://podcasters.spotify.com/pod/show/syngap10/message

Inspiring Events, Family Video & Important Studies. *Note the CINEMAS TRIAL for Epidiolex - #S10e107   RECENT EVENTS MDBR Blog https://www.syngapresearchfund.org/post/mdbr-2023-everything-we-want-to-c-happening-for-syngap1-camaraderie-community-collaboration   Paddle Slap video https://www.youtube.com/watch?v=F9SaHPzd5bU Paddle Slap blog https://www.syngapresearchfund.org/post/syngap-paddle-slap-is-a-thing   Family Video and Fundraiser: Shaeffer Video https://www.youtube.com/watch?v=Z_dI059yPeM Shaeffer Fundraiser https://secure.givelively.org/donate/syngap-research-fund-incorporated/support-srf-for-story-s-19th-birthday   SRF in the World: SRF in Mexico - Our Voice is Getting Louder blog Syngap.Fund/Voice SRF in Poland - https://twitter.com/beatasyngap1/status/1664996361585197057?s=20   STUDIES ENDD S1 NHS - Email ENDD@chop.edu to sign up and please cc mike@curesyngap1.org, lauren@curesyngap1.org & sydney@curesyngap1.org - https://drive.google.com/file/d/1ASUkKQOgjbs9hkJVCJ40N8MbVFH4X9_h/view# CHOP NHS ENDD Blog: https://Syngap.Fund/CHOPNHS   CORNELL English https://redcap.link/syngapcaregiversurvey Spanish https://redcap.ctsc.weill.cornell.edu/redcap_protocols/surveys/?s=MWTW743PHENPPRPY   COMBINEDBrain Biorepository https://www.syngapresearchfund.org/webinars/74-combinedbrain-biobank-our-partnership-with-srf-for-syngap1 STXBP1 Foundation, (July 21st-23rd 2023; 10600 Westminster Blvd, Westminster, CO 80020) Yellow Brick Road Project, (July 30th-August 2nd (Ponte Vedra Lodge & Club, 607 Ponte Vedra Blvd, Ponte Vedra Beach, FL, 32082)   CINEMAS STUDY - Mild Intellectual Delay https://cinemasstudy.com/#right_for_me    PRESS Axios Fruit Flies article https://www.axios.com/local/salt-lake-city/2023/06/09/fruit-fly-medical-research-university-utah   FUTURE EVENTS June 21 - Splash for Syngap https://www.syngapresearchfund.org/post/share-your-love-for-someone-with-syngap1-for-splash4syngap August 26 - Syngap Soiree  https://e.givesmart.com/events/wiH October 7 - Scramble for Syngap https://secure.givelively.org/event/syngap-research-fund-incorporated/scramble-for-syngap-2023 October 21 - SynGAP Research Fund Gala Honoring Caren Leib - https://e.givesmart.com/events/wBy/ October 30-31 - Epilepsy Awareness Day at Disneyland  https://epilepsyawarenessday.org/lobby-page/ Nov 30-Dec 1 - SYNGAP1 Conference 2023 hosted by SynGAP Research Fund https://www.syngapresearchfund.org/professionals/syngap1-roundtable-2023-syngap-research-fund Conference pre-registration link: Syngap.Fund/2023conf Book hotels ASAP: https://Syngap.Fund/2023hotel T-shirts https://www.bonfire.com/srf-syngap1-conference-2023/ WEBINARS Upcoming: June 15 - Quantifying perturbed SYNGAP1 Function Caused by Coding Mutations - Dr. Michael Courtney from Turku in Finland https://www.syngapresearchfund.org/webinars/79-quantifying-perturbed-syngap1-function-caused-by-coding-mutations   - Previous: Therapeutic Strategies for Autism: Targeting Three Levels of the Central Dogma of Molecular Biology - Presented to the SYNGAP1 Community - Lilia Iakoucheva & Derek Hong https://www.syngapresearchfund.org/webinars/78-therapeutic-strategies-for-autism-targeting[…]tral-dogma-of-molecular-biology-with-a-focus-on-syngap1   PODCAST - Syngap Stories, interviews, see #10 with Dani Williams  https://www.syngapresearchfund.org/podcast-episodes/episode-010   Volunteer with SRF! Info@SyngapResearchFund.org    This is a podcast: subscribe to and rate this 10 minute #podcast #SYNGAP10 here  - https://www.syngapresearchfund.org/syngap10-podcast Apple podcasts:  https://podcasts.apple.com/us/podcast/syngap10-weekly-10-minute-updates-on-syngap1-video/id1560389818 Episode 107 of #Syngap10 - June 14, 2023 #epilepsy #autism #intellectualdisability #id #anxiety #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology #GeneChat

First off, apologies from our team for the late posting, I had a sudden medical emergency myself that put me in the hospital.  But... we are back and will be posting a new episode on that incident in the near future!  Thank you for trusting us to return to show production, even if we are 30 hours late!  We are running with back to back reruns based on listeners requests.  For this week's show, let me re-introduce you to Meg Pecora from our first season in July of 2018. At the time Meg was a recent college graduate from Columbia in Chicago. Now she is a recently engaged artist with chronic pain due to Fibromyalgia.  She was approved for the Illinois medical cannabis program and discusses the process of obtaining the authorization and finally "prescription" for medical cannabis as a pain reliever.  ​ Medical marijuana uses the marijuana plant or chemicals in it to treat diseases or conditions. It's basically the same product as recreational marijuana, but it's taken for medical purposes. The marijuana plant contains more than 100 different chemicals called cannabinoids. Each one has a different effect on the body. Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the main chemicals used in medicine. THC also produces the "high" people feel when they smoke marijuana or eat foods containing it. ​"The greatest amount of evidence for the therapeutic effects of cannabis relate to its ability to reduce chronic pain, nausea and vomiting due to chemotherapy, and spasticity [tight or stiff muscles] from MS," Bonn-Miller says. ​Medical marijuana received a lot of attention a few years ago when parents said that a special form of the drug helped control seizures in their children. The FDA recently approved Epidiolex, which is made from CBD, as a therapy for people with very severe or hard-to-treat seizures. In studies, some people had a dramatic drop in seizures after taking this drug.  ​The cannabidiol Epidiolex was approved in 2018 for treating seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome. In addition, the FDA has approved two man-made cannabinoid medicines -- dronabinol (Marinol, Syndros) and nabilone (Cesamet) -- to treat nausea and vomiting from chemotherapy.  ​ (credits: WEBMD & Marcel Bonn-Miller Ph.D.)

In this episode, Ayesha talked about the FDA approval of Ferring Pharmaceuticals' fecal matter-based therapy Rebyota for the treatment of recurrent C. difficile infections. While fecal matter transplants (FMT) have been a standard of care for recurrent CDIs, despite not having formal approval, Rebyota has become the first FDA approved FMT-based treatment for CDIs. Hear more about the drug and its approval in this episode. Ayesha also discussed a new CBD oral capsule being developed by PureTech Health for the treatment of epilepsy and potentially other indications as well. The drug will be going up against Jazz Pharma's Epidiolex, which was first approved in 2018 for the treatment of seizures associated with rare types of epilepsy. Hear about the advantages of an oral capsule formulation of CBD, including lower costs and not requiring the use of sesame oil.Read the full articles here:FDA Approves Rebyota as First Fecal Microbiome Therapy for Recurrent C. Difficile InfectionPureTech Reveals New CBD Pill to Rival Jazz's EpidiolexFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Treatment options for problematic behaviors associated with severe autism are limited. Can cannabidiol (CBD) be an effective therapy? Doris Trauner, M.D., discusses recent studies looking at the use of CBD and how it works in the brain. Series: "Autism Tree Project Annual Neuroscience Conference" [Health and Medicine] [Show ID: 38393]

Treatment options for problematic behaviors associated with severe autism are limited. Can cannabidiol (CBD) be an effective therapy? Doris Trauner, M.D., discusses recent studies looking at the use of CBD and how it works in the brain. Series: "Autism Tree Project Annual Neuroscience Conference" [Health and Medicine] [Show ID: 38393]

Treatment options for problematic behaviors associated with severe autism are limited. Can cannabidiol (CBD) be an effective therapy? Doris Trauner, M.D., discusses recent studies looking at the use of CBD and how it works in the brain. Series: "Autism Tree Project Annual Neuroscience Conference" [Health and Medicine] [Show ID: 38393]

Treatment options for problematic behaviors associated with severe autism are limited. Can cannabidiol (CBD) be an effective therapy? Doris Trauner, M.D., discusses recent studies looking at the use of CBD and how it works in the brain. Series: "Autism Tree Project Annual Neuroscience Conference" [Health and Medicine] [Show ID: 38393]

Treatment options for problematic behaviors associated with severe autism are limited. Can cannabidiol (CBD) be an effective therapy? Doris Trauner, M.D., discusses recent studies looking at the use of CBD and how it works in the brain. Series: "Autism Tree Project Annual Neuroscience Conference" [Health and Medicine] [Show ID: 38393]

Cresco Labs & Columbia Care Deal Make Sean Combs The First Minority Owner of Multi-State Cannabis Operation  Cannabis Industry Can't Even Catch A Break In Tax Settlements Dentists Say Half Their Patients Show Up High Cannabis Medicine, What's The Difference Between Sativex, Marinol, and Epidiolex

What's wrong with the cannabis industry?Joining us again on the latest episode of The Cannabis Conversation is Dr Ethan Russo, Founder of Credo Science -  a novel medical science company.We discuss the prejudice and ignorance against Cannabis, as well as safety monitoring, legalisation and some of the challenges the industry is facing, including a lack of proper funded research in the area.The Cannabis Conversation is sponsored by Lumino - a boutique HR and Recruitment Agency specialising in building high performance teams for the European Cannabis Industry. They work in three main verticals: Commercial, Medical and Plant Facing.Get in touch at www.luminorecruit.com/About Ethan RussoEthan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Founder/CEO of CReDO Science https://credo-science.com He is also Medical Director of Andira Pharmaceuticals Andira – Bringing Healing to Life and Senior Medical Advisor to Canurta Home | CanurtaPreviously he was Director of Research and Development for the International Cannabis and Cannabinoids Institute, 2017-19, Medical Director of PHYTECS, 2015-2017, and from 2003-2014, Senior Medical Advisor, medical monitor/study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex® and Epidiolex®.He was a clinical neurologist in Missoula, Montana for 20 years. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, and in Medicine at the University of Washington. He is author/editor of seven books and has published more than 50 peer-reviewed articles.ResourcesJoin Dr. Russo on LinkedIn: https://www.linkedin.com/in/ethan-russo-md-468b19a/View Dr. Russo's clinical research papers: https://www.researchgate.net/profile/Ethan_RussoCReDO Science Website: https://credo-science.com/

Dr. Ethan Russo and Nishi Whiteley have worked together for almost 10 years in efforts to:improve the scientific understanding of the endocannabinoid system (ECS) and how the cannabis plant modulates itassist small and large cannabis companies in product formulationadvise companies on cannabis genetics enhancementsconsult on pre-clinical and clinical research design.“We share a vision of making cannabis better and safer believing in a future in which knowledge of the endocannabinoid system and its therapeutic modulation via the cannabis plant will result in superior highly individualized medicines, aids to wellness, enhanced lifestyles, and novel non-toxic industrial products”.Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and author. He is the Founder and CEO of CannabisResearch.org. Previously, he was Director of Research and Development at the International Cannabis and Cannabinoids Institute (ICCI) based in Prague, Czech Republic. Medical Director of PHYTECS (2015-2017), a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system, and from 2003-2014, he served as Senior Medical Advisor, medical monitor, and study physician to GW Pharmaceuticals, United Kingdom for numerous Phase I-III clinical trials of Sativex® for alleviation of cancer pain unresponsive to optimized opioid treatment and initial studies of Epidiolex® for intractable epilepsy.Nishi Whiteley (pronounced Nee-sha), is the co-founder and Chief Operating Officer at CReDO. She has twenty-five-plus years of international business development experience in cannabis, agriculture, wellness, green energy, and food industries. She has had leadership roles on projects in corporate America and for the US Foreign Ag Service in over 10 countries, in startups, a state agency, and non-profits; as well as worked for foreign governments and met with international leaders in Cuba, Mexico, and the Dominican Republic to open trade and advance development programs. She has worked on investment projects in 8 countries.

A bit more about our main takeaways from our chat with Dr. Callie Seaman on cannabis and epilepsy. We take a deeper look into Epidiolex, the CBD pharmaceutical that is prescribed for epilepsy and the possible molecular mechanisms that underlie the effects. We also talk about chemodiversity which is our favorite part of the what the cannabis plant has to offer therapeutically. Next week we're covering our favorite topic: the science o' smoke! Disclaimer: Everything in this podcast is the opinion of the hosts and those interviewed; this is not medical advice. - - - - - - Try Our Products: www.profoundnaturals.com Contact Us: www.smokenscience.com Instagram: instagram.com/smokenol YouTube: youtube.com/c/smokenol Reddit: reddit.com/r/smokenscience If you are a licensed processor who is interested in working with us contact us at sales@smokenol.com !

Does marijuana cause mental illness and violence? Alex Berenson published a doctorate type research in his book - Tell Your Children. Alex is also known for being cancelled by Twitter for his views on the COVID vaccine. Alex Berenson was born in New York in 1973 and grew up in Englewood, N.J.  After graduating from Yale University in 1994 with degrees in history and economics, he joined the Denver Post as a reporter. In 1996, he became one of the first employees at TheStreet.com, the groundbreaking financial news Website. In 1999, he joined The New York Times. At the Times, he covered everything from the drug industry to Hurricane Katrina; in 2003 and 2004, he served two stints as a correspondent in Iraq, an experience that led him to write The Faithful Spy, his debut novel, which won the Edgar Award from the Mystery Writers of America for Best First Novel. He left the Times in 2010 to devote himself to writing fiction. But conversations with his wife led him to begin researching the science around cannabis and mental illness, a project that became the book Tell Your Children, published in January 2019. He has now written twelve John Wells novels and two non-fiction books, The Number and Tell Your Children. Alex lives in the Hudson Valley with his wife, Dr. Jacqueline Berenson, a forensic psychiatrist, and their children. FDA Label for Marinol, THC FDA Label for Epidiolex, CBD

¿Por qué las etiquetas de productos de CBD tienen tantas inconsistencias? Según una encuesta de Gallup de 2019, una de cada siete personas en los Estados Unidos usa CBD al menos una vez al día.A pesar de la popularidad del producto, la mayoría desearía saber más sobre qué contienen exactamente las bebidas, los aceites, los tópicos y otros productos que utilizan. Este curiosidad es inteligente, porque lo que está en la etiqueta puede no reflejar lo que está en el producto.La legalización del cáñamo en los EE.UU. ha llevado a un tremendo crecimiento en la disponibilidad de productos derivados del cáñamo, particularmente productos de cannabidiol (CBD). Sin embargo, la falta de supervisión regulatoria en esta industria ha resultado en la comercialización y venta de productos de CBD con ingredientes y calidad cuestionables.El objetivo de un estudio de 2022 fue examinar el contenido en 80 productos de CBD derivados del cáñamo disponibles comercialmente y comprados a minoristas locales y en línea. Epidiolex® también se incluyó en el estudio como control positivo.El quince por ciento de las muestras contenía menos del 90% de la concentración declarada en la etiqueta, y alrededor del 31 % de las muestras contenía más del 110 % de la concentración declarada en la etiqueta, dice un informe de National Library of Medicine En general, menos de la mitad de las 80 muestras analizadas estaban dentro del 10% de la concentración de CBD declarada en la etiqueta.Aunque el CBD ya no es una sustancia controlada, la Administración de Drogas y Alimentos supervisa la veracidad de las etiquetas y es responsable de abordar las declaraciones falsas o engañosas que aparecen en las etiquetas de los productos de CBD.El "Estudio de precisión de la etiqueta" mencionado anteriormente es similar a un estudio de Bonn-Miller de 2017, que también encontró que los extractos de CBD tienen imprecisiones en la etiqueta. De 84 muestras en este estudio, aproximadamente el 43 % no estaba debidamente etiquetado y solo el 31 % estaba etiquetado con precisión.Hay una serie de razones para las etiquetas inexactas. En primer lugar, existen pocos métodos de prueba estándar robustos, lo que lleva a cada laboratorio a desarrollar el suyo propio.Si quieres conocer más acerca de “Cuánto tiempo dura el CBD en el organismo. Epi 122” te dejaré el enlace al episodio en las notas de esta edición.Las diferencias en los métodos de prueba pueden incluir la preparación de la muestra, la extracción y la tecnología, por ejemplo y además, cada laboratorio utiliza diferentes protocolos para el control de calidad. Eso puede incluir diferencias en el tipo de controles, especificaciones y, en última instancia, las bandas de confianza y las reglas de control de calidad. También, las especificaciones tanto para los protocolos de prueba como del control de calidad pueden estar determinadas por la gran cantidad de requisitos reglamentarios que no siempre son prácticas aceptadas en química analítica.Los informes de 2022 y Bonn-Miller, publicados con cinco años de diferencia, muestran que la industria no ha logrado mejorar la precisión de las afirmaciones de las etiquetas.Ambos estudios respaldan la enorme necesidad de métodos de prueba estandarizados robustos que estén impulsados ​​por datos derivados empíricamente basados ​​en protocolos rigurosos de validación múltiples laboratorios. De lo contrario, seguiremos teniendo etiquetas inexactas y los consumidores se verán obligados a tomar decisiones basadas en etiquetas inválidas que pueden comprometer su salud física o su bienestar psicológico y malgastar su dinero.También podemos esperar demandas judiciales, como una demanda colectiva de $500 millones en 2020 iniciada por consumidores canadienses que afirmaron que las etiquetas de los productos no cumplían con sus expectativas, detalló Susan Audino, consultora de química e instructora de la Asociación Estadounidense de Acreditación de Laboratorios.

Part 4 of 4 of our multi-part series: Expanding Access and CBD Therapies for People with Developmental DisabilitiesEpisode 4: Epidiolex (cannabidiol) & Developmental DisabilitiesFeaturing: Laura Borgelt, PhramD, MBA at CU Anschutz Medical Campus-What Epidiolex is and what it's currently approved for;-Learn about continuing research on Epidiolex use for other disabilities and health conditions;-How you can have a conversation with your physician about exploring Epidiolex; and-The difference between Epidolex and retail CBD; and-How you can safely navigate products.

Hemp Industry Episode Resources:Host: Jonathan MillerGuest: Dr. Robert KaufmanBlog: Hemp Legally SpeakingHemp Industry questions covered in the episode: What does the ValidCare study demonstrate about the safety of ingestible CBD? What did the study conclude about CBD's liver toxicity and how does this contrast with studies done on Epidiolex, the CBD drug used by children with rare forms of epilepsy? How does the study address concerns about drowsiness and low testosterone? Statistically speaking, how strong are the study's conclusions What's the message that Dr. Kaufman will be sharing with FDA in its upcoming meeting?

Who should use CBD, how should you procure it and how much should you take? Learn all about the risks, benefits and scientific evidence that supports the role of CBD in health.Join Kathleen and RDN Janice Bissex, a holistic cannabis practitioner, and Program Director of Cannabinoid Medical Sciences at John Patrick University School of Integrative & Functional Medicine. Janice is also an author of Simple Guide to CBD: Fact, Fiction, and a Path ForwardWithout sufficient high-quality evidence in human studies, we can't pinpoint effective doses, and because CBD currently is typically available as an unregulated supplement, it's hard to know exactly what you are getting.Key Messages:CBD and THC are cousins but serve vastly different purposes.  CBD is not intoxicating.  Marijuana contains THC and is psychoactive.  Legally, CBD products can only contain .03% THC.If you decide to try CBD, talk with your doctor to make sure that it won't affect any other medicines you take.In numerous studies, CBD was able to reduce or stop seizures. Epidiolex, which contains CBD, is the first cannabis-derived medicine approved by the FDA.Buyer beware, since CBD is not regulated so purchase from a reputable source and request a certificate of analysis. According to a report from the World Health Organization, "In humans, CBD exhibits no effects indicative of any abuse or dependence potential” and is considered safe. CBD is a plant that contains over 100 ingredients including health promoting terpines, cannabinoids, hemp, flavonoids and more. https://www.jannabiswellness.com

Welcome to Cannabis Daily - Your daily guide to cannabis news, industry trends, and trade ideas in under 5 mins.Innovative Industrial Properties Reports Unaudited Q1 2022 Revenue Growth Of 50% To $64.5M YoY.Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY.Green Thumb Industries Reports Strong Q1, Ninth Consecutive Quarter Of Positive Cash Flow.Cannabis Tech Provider Weedmaps Acquires Enlighten, An Ad And Menu Biz.Needham Maintains Buy on Green Thumb Industries, Lowers Price Target to $26.Stocks To Watch Today:MAPSJAZZIIPRMRMDHosted & Produced By:Elliot LaneAaron ThomasContact us at: cannabishour@benzinga.comFollow Benzinga Cannabis On Social MediaInstagramTwitterYouTubeLinkedInSubscribe to all Benzinga Podcasts at https://www.benzinga.com/podcastsSubscribe to the Cannabis Insider Newsletter to get more cannabis news and trending links delivered to your inbox.Tune in weekly to Cannabis Insider at 4 pm ET every Tuesday &Thursday for Cannabis News & Executive Interviews at bzcannabishour.comHit us up at https://www.benzinga.com/cannabis/ for more news today, tomorrow, and everyday.Access All The Cannabis Daily Episodes HereFor Top Gainers & Losers Cannabis stocks of the day check out https://www.benzinga.com/cannabis/stocksGood morning, my friends hope you're having a wonderful start to your Thursday. This is Elliot lane, host of cannabis daily with Benzinga, bringing you your daily dose of cannabis insights and market news. We do have quite a bit of interesting items to get to today. Several big companies reporting their first quarter performance, a few product updates as well as an interesting claim From a large Canadian licensed producers CEO.So let's dive right in GTI green thumb industries, OTC listed GTB. I F reports their first quarter performance of 2022, their sales or flat sequentially dropping less than 1% EBITDA margin falls for the fourth straight quarter per Pablo's Wantage. The company is refraining from offering guidance, but is looking like the second quarter of 2022.Flat sales growth, positive regional specific developments in New Jersey, obviously Virginia and Minnesota, but overall macro trends, including price deflation may counteract that positive growth. Pablo remains overweight and keeps the price target at 30. Pablo on Weedmaps, which also reported its first quarter earnings.He remains overweight, but raises the price target to $11 30 cents from $7 65 cents a decent jump. Their sales were 3% higher. Then the high end of the company's guidance props to Chris Beales and team on that one 40% year over year sales growth maintained their calendar year sales guidance of 255 to 265 million.And they project the second quarter sales of 60 to 63 million over. Weed maps is probably one of the darling stocks of this industry. Right now. If you don't have them on a watch list, you should put them there. There's a lot of great tailwinds for this company. Such as expansion every time this industry expands footprint, retail, more stores.It is a positive development for a company like weed maps and as their technology grows, so will their product suite. So they have a long runway to grow that 250 plus million year yearly sales now. Epidiolex the CBD based medicine founded by GW pharma, which was acquired by jazz pharmaceuticals.So the stock is jazz. Their net product sales of Epidiolex were up 6% year over year to 157.9 million. Now commercially available in the UK, Germany, Italy, and Spain, as well as Switzerland, Ireland and Norway. With an anticipated launch in France this year as well. There are launching phase three trial for epilepsy with myoclonic atonic seizures in the first half of 2022.There is no other leader in. This part of the cannabis space on the biotech side than jazz. It's just really impressive numbers there. I P R this is innovative industrial properties, as we all know, total revenues in the first quarter of 2022 up 50% year over year 9% sequentially. In the quarter I IP made six property acquisitions in Arizona, California, Maryland, Massachusetts, New Jersey and Pennsylvania.They established a relationship with Verano and expanded relationships with forefront. Ascend pharma can truly leave with news with others on both fronts as. The Tetra bio-pharma OTC listed TB PMF partners with Canva late to launch trials of three potential medicines in Australia can violate also investing seven and a half, seven and a half million Canadian dollars into Tetra.They'll receive a heavy tax credit in Australia. Tetra is a biopharma company focused on cannabinoids, and here we go. This is a. Interesting claim here, the leading cannabis CEO or a leading cannabis CEO, I should say in Canada, Zack George from sundial, S and D L on the NASDAQ claims hundreds, if not over a thousand stores may close.He gave no specific reason. So little doom and gloom for you there. No. It just is a quote at the moment, but something to that we need to report on and make sure we have on the record there from Zack Mira, med solidifies, vertical integration in Illinois, that's OTC listed M R M D with closing of the acquisition.It has of a state craft cannabis license holder. If I am looking at winners today, I think maps map S is probably my leader, jazz J a Z as well as I P. You know what mayor men in there as well, we'll do four for the day. That's it for today though. Thank you so much for tuning in rate and review us tune in today.Cannabis insider four o'clock Eastern time. If you're listening to this, not on Thursday, May 5th, go back and rewatch it. We have an incredible announcement today on the show with Javier and major company that may or may not have been mentioned in this podcast. Thanks again. Y'all we'll talk.Support this podcast at — https://redcircle.com/cannabis-daily/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

In this episode, Ayesha discussed Pfizer's voluntary recall of several lots of its blood pressure medication Accuretic and two generic versions of it due to higher than acceptable levels of a carcinogenic nitrosamine compound. The recall affects lots produced between November 2019 and March 2022. The editorial team discussed the increasing frequency of recalls of commonly prescribed drugs like blood pressure and diabetes medications. Should companies and regulators share more information about the steps being taken to address the issue of drug impurities?The editorial team also talked about Jazz Pharmaceutical's new $100 million manufacturing facility in the UK dedicated to the production of cannabis-based medicines. This includes the company's bestselling epilepsy drug Epidiolex, which is the first FDA-approved cannabis-based medication. Construction on the facility has commenced and Jazz says it is committed to it being environmentally sustainable at all stages of development and use. Find out how Jazz is going green with its new cannabis-based drug manufacturing facility. Read the full articles here: Accuretic Blood Pressure Drug and Two Generics Recalled by Pfizer Over Carcinogen ImpuritiesJazz Pharma Announces $100 Million “Green” Manufacturing Plant for Cannabis-Based MedicinesFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Nick Jikomes talks to cancer biologist Dr. Marsha Rosner, who is a Professor of Cancer Research at the University of Chicago. Her lab focuses largely on understanding the biochemical signaling mechanisms that lead to the generation of tumor cells, as well as how and why cancer cells metastasize, which is when they travel from one part of the body to another.Nick and Dr. Rosner and discuss mainly a recent study she led about the antiviral effects of cannabidiol (CBD) against SARS-CoV-2, including: why a cancer lab was working with CBD to begin with; what the results of her study actually show in terms of CBD's antiviral effects; whether other cannabinoids showed this effect. She also commented on some misconceptions that have been circulating regarding this work, and described some of the clinical trials her team is running to measure CBD's potential as an anti-COVID drug.USEFUL LINKSSign up for the weekly Mind & Matter newsletter[https://mindandmatter.substack.com/?sort=top]Download the podcast & follow Nick at his website[https://www.nickjikomes.com]Follow Nick's work through Linktree:[https://linktr.ee/trikomes]Athletic Greens, comprehensive daily nutrition (Free 1-year supply Vitamin D w/ purchase)[https://www.athleticgreens.com/mindandmatter]Organize your digital highlights & notes w/ Readwise (2 months free w/ sub)[https://readwise.io/nickjikomes/]Learn more about our podcast sponsor, Dosist[https://dosist.com]Support the show (https://www.patreon.com/nickjikomes)

Cannabidiol (CBD) is a powerful plant-based compound used to help with a variety of issues, as shown in the studies below. However, despite these studies, it is important to note that the FDA has not approved any products (other than Epidiolex) for the diagnosis, cure, mitigation, treatment, or prevention of any disease. Additionally, CBD can have adverse effects if consumed with other medications. As such, we recommend consulting your physician prior to using any CBD product. If you have any questions about CBD or our various products, please contact us at support@rxremediesinc.com or at (888) 797-3601. We are here to assist you. rxremediesinc.com

Business of Cannabis was the Platinum Media Partner for the Lift&Co. Expo in Toronto in November 2021. During the show, the Business of Cannabis team sat down with key leaders in the cannabis sector for conversations about where the industry is right now. This conversation was part of those sessions.Dr. Evan Cole Lewis is a Pediatric Neurologist and Clinical Neurophysiologist with expertise in epilepsy, epilepsy surgery, electroencephalography (EEG), teleneurology and medical cannabis for the treatment of neurologic disorders. Dr. Lewis is the director of the Neurology Centre of Toronto (NCT) which he established in January 2017. At NCT, Dr. Lewis treats children with a variety of neurological disorders and he also treats adults for concussion, headache and epilepsy. Dr. Lewis' interest in medical cannabis began in 2013 while training at Miami Children's Hospital – one of the major sites for the Epidiolex trials. He has significant clinical experience with medical cannabis in adults and children and is a member of the Canadian Consortium for the Investigation of Cannabinoids (CCIC), Canadian Childhood Cannabinoid Clinical Trials (C4T), and the Cannabinoid Research Initiative of Saskatchewan (CRIS).BofC Live is the daily news and interview program of Business of Cannabis. Business of Cannabis highlights the companies, brands, people and trends driving the sector.

CBD and other cannabinoids are really hot right now and according to Google health trends, mentions and prominence of CBD are up 2500% in the past 5 years. It's gone from an unknown entity, kind of a fringe sort of thing, to one of the hottest ingredients on Earth when it comes to human health. Many of us know someone who has taken it and seen great results. Cannabis cells are estimated to be 30.6 billion dollars in 2021 and to increase by 41% to 62.1 billion by 2026 with a compound annual growth rate of 15%. CBD is likely not going away and I will talk about the legal status, the basics of what CBD is, what some of the properties are, what its mechanism of action is, health benefits, legal status, safety, and some key takeaways. The cannabis sativa plant 1:42Cannabinoids 3:16Health benefits 7:27THC 12:56Legal status 15:34Some issues 23:22“So there was a clinical study published in Lancet Neurology in 2015 on 214 patients and they showed a significant drop in seizures in 36% of these patients who had treatment resistant epilepsy. Sam was one of those from Berkeley, California and he was the first patient to try Epidiolex. Before, and on all sorts of anti-epileptic drugs, he was having 100 seizures a day. After one day on Epidiolex, Sam's seizures were down to 30. 2 days, he was down to 10 seizures a day, and on day 3 he had one seizure and there were no side effects for Sam. ” 9:39

Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and author. He is the Founder and CEO of CReDo Science www.credo-science.com In this episode, Dr. Ethan Russo talks to us about his new study on CBG, ‘the mother of all cannabinoids', cannabinoid acids, and affordable diagnostics for the endocannabinoid system that provide needed information for patients and doctors. This technology could improve outcomes and product choices for all phyto-therapies, such as aromatherapy, herbalism, and cannabinoid therapy, which Dr. Russo believes can be much more nimble than one-size-fits-all pharmaceuticals in addressing the individualized needs of the patient. Previously, he was Director of Research and Development of the International Cannabis and Cannabinoids Institute (ICCI) based in Prague, Czech Republic: https://www.icci.science. Medical Director of PHYTECS (2015-2017), a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system (http://www.phytecs.com), and from 2003-2014, he served as Senior Medical Advisor, medical monitor and study physician to GW Pharmaceuticals, United Kingdom for numerous Phase I-III clinical trials of Sativex® for alleviation of cancer pain unresponsive to optimized opioid treatment and initial studies of Epidiolex® for intractable epilepsy (https://www.gwpharm.com). He graduated from the University of Pennsylvania (Psychology), and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child and Adult Neurology at the University of Washington in Seattle. He was a clinical neurologist in Missoula, Montana for 20 years in a practice with a strong chronic pain component. In 1995, he pursued a 3-month sabbatical doing ethnobotanical research with the Machiguenga people in Parque Nacional del Manu, Peru. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences, Harvard University, and Johns Hopkins University. He is a Past-President of the International Cannabinoid Research Society and is former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council. He is author of Handbook of Psychotropic Herbs, co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, and author of The Last Sorcerer: Echoes of the Rainforest. He was founding editor of Journal of Cannabis Therapeutics, selections of which were published as books: Cannabis Therapeutics in HIV/AIDS, Women and Cannabis: Medicine, Science and Sociology, Cannabis: From Pariah to Prescription, and Handbook of Cannabis Therapeutics: From Bench to Bedside. He has also published numerous book chapters, and over sixty articles in neurology, pain management, cannabis, and ethnobotany. His research interests have included correlations of historical uses of cannabis to modern pharmacological mechanisms, phytopharmaceutical treatment of migraine and chronic pain, herbal synergy and phytocannabinoid/terpenoid, serotonergic and vanilloid interactions. He has consulted or lectured on these topics in 44 US states and Canadian provinces and 44 countries on six continents.Useful Links:https://credo-science.com/projects/CBG StudyCReDoEndo DNA testsEurofins worldwide testinghttps://ethanrusso.org/category/library/ To learn more about plants & your health from Colleen at LabAroma check out this informative PDF: https://mailchi.mp/2fe0e426b244/osw1lg2dkhDisclaimer: The information presented in this podcast is for educational purposes only and is not intended to replace professional medical advice. Please consult your doctor if you are in need of medical care, and before making any changes to your health routine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Karen Keough, MD Guest: Dawn S. Eliashiv, MD Dr. Dawn Eliashiv of the University of California—Los Angeles and Dr. Karen Keough of the Child Neurology Consultants of Austin, Texas discuss using EPIDIOLEX® to treat patients 1 year of age or older with seizures associated with LGS, Dravet syndrome, or TSC.

J and D talk to Codi Peterson, owner of PharmD Approved, about the Endocannabinoid System (ECS) -- the physiological system in our bodies that responds to cannabis.  He shares what products are available to pediatric patients suffering from seizures and cancer. Codi also gets D to make a big confession and crushes the myth about cannabis and our memory. Our guest reviewer, G, tells listeners about the surprising efficacy of the CBD product he consumes in order to alleviate the pain of Crohn's disease. Vocabudulary lesson: endocannabinoid system, aka ECS (n.): the complex cell-signaling system identified in the early 1990s by researchers exploring THC, a well-known cannabinoid.Epidiolex (n.): the first FDA‑approved prescription cannabidiol used to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older.Marinol (n.): a man-made form of cannabis used to treat patients suffering from loss of appetite, nausea and vomiting due to cancer and chemotherapy.transmucosal (adj.): supplying a medication through or across a mucous membrane (as of the mouth).

Bright Minds Biosciences Inc (CNSX:DRUG, OTCMKTS:BMBIF) is a biotech company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Our viewers may be familiar with GW Pharmaceuticals PLC (formerly NASDAQ:GWPH), recently acquired by Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), and its Epidiolex® (CBD) oral solution as a treatment for childhood-onset epilepsy. Bright Mind’s focus is on […]

What is Cannabinoid Hyperemesis Syndrome (CHS)?This week, we welcome back Dr. Ethan Russo, physician, researcher, and leading expert in the field of Medicinal Cannabis. In this episode, Dr Russo shares the latest research and findings of the largest study on CHS to date - in which his team identified 6 potential genetic targets to assist in the diagnosis and treatment of the condition.→ View full show notes, summary, and access resources here: https://www.canverse.global/shownotes/e120About Dr. Ethan RussoEthan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Founder/CEO of CReDO Science https://credo-science.com Previously he was Director of Research and Development for the International Cannabis and Cannabinoids Institute, 2017-19, Medical Director of PHYTECS, 2015-2017, and from 2003-2014, Senior Medical Advisor, medical monitor/study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex® and Epidiolex®.He was a clinical neurologist in Missoula, Montana for 20 years. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, and in Medicine at the University of Washington. He is author/editor of seven books and has published more than 50 peer-reviewed articles.ResourcesJoin Dr. Russo on LinkedIn: https://www.linkedin.com/in/ethan-russo-md-468b19a/View Dr. Russo's clinical research papers: https://www.researchgate.net/profile/Ethan_RussoCReDO Science Website: https://credo-science.com/Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation Paper: https://pubmed.ncbi.nlm.nih.gov/34227878/

กัญชา สมุนไพรที่อยู่คู่กับมนุษย์มาอย่างช้านาน ทั้งในเรื่องของการใช้เพื่อสันทนาการ และการนำประโยชน์มาใช้ในทางการแพทย์ แล้วกัญชานั้นแบ่งออกเป็นกี่สายพันธุ์ มีข้อดี ข้อเสีย หรือข้อควรระวังในการใช้อย่างไรบ้าง มาติดตามได้ในรายการ Dr.Amp Podcast เรื่องเล่าสุขภาพดี กับ หมอแอมป์ ตอน "กัญชา คุณค่าสมุนไพรจากธรรมชาติ" โดย นพ. ตนุพล วิรุฬหการุญ -ประธานเจ้าหน้าที่ปฏิบัติการ และ ผู้อำนวยการ BDMS Welness Clinic -ผู้อำนวยการ RoyalLife โรงพยาบาลกรุงเทพ -นายกสมาคมแพทย์ฟื้นฟูสุขภาพและส่งเสริมการศึกษาโรคอ้วน กรุงเทพ (BARSO) สามารถค้นหารายชื่อแพทย์ที่ผ่านการอบรมหลักสูตรการใช้กัญชาที่กรมการแพทย์ หรือ กรมการแพทย์แผนไทยและการแพทย์ทางเลือกให้การรับรองได้ที่: http://hemp.fda.moph.go.th/FDA_MARIJUANA/SAS/VISIT_DOCTOR

Con Viola Brugnatelli oggi parliamo di Cannabis, di Epidiolex e della direzione del CBD e delle infiorescenze di canapa in Italia.

Good Morning Veterans, Family, and Friends, welcome back to the TWENTY-FOURTH EPISODE of the Veteran Doctor. On this week's episode, we will discuss Veterans PTSD – The Cannabis Cure. Marijuana Use for PTSD Among Veterans The use of Marijuana for medical conditions is an issue of growing concern. Many Veterans use marijuana to reduce symptoms of PTSD, and many states specifically approve medical marijuana for PTSD. However, research has not been conducted on the safety or effectiveness of medical marijuana for PTSD. There is no evidence currently that suggests marijuana is an effective treatment for PTSD. This research indicates that marijuana can be harmful to individuals with PTSD. Epidemiology Marijuana use has increased over the past decade. In 2013, a study found that 19.8 million people reported using marijuana in the past month, with 8.1 million using it almost every day (1). Daily use has increased by 60% in the prior decade (1). Several factors are connected with increased risk of marijuana use, involving diagnosis of PTSD (2), social anxiety disorder (3), other substance use, mainly through youth (4), and peer substance abuse (5). Cannabis Use Disorders among Veterans Using VA Health Care There have currently been no studies of marijuana use conducted on the overall Veteran population. The data we have gathered comes from Veterans using VA health care, who may not represent the Veteran population overall. When considering this subset of veterans seen in the VA health care with co-existent of substance use disorders (SUD) and PTSD, cannabis use disorder has been the most diagnosed SUD since 2009. Veterans in the VA with PTSD and SUD diagnosed with cannabis use disorder increased from 13.0% in FY 2002 to 22.7% in FY 2014. As of FY 2014, more than 40,000 Veterans with PTSD and SUD are seen in VA diagnosed with cannabis use disorder. People in 33 States can use medical Marijuana. Why Haven't Veterans Been able to Use It for PTSD? Dogs have been prescribed medical marijuana, but veterans still cannot get the drug from the Veterans Affairs. Several Veterans groups are working on getting medical marijuana approved as a form of treatment for PTSD. The Department of Veterans Affairs (VA) still refuses to provide marijuana to veterans because it is listed as a Schedule I drug. Many Veterans groups want to get that designation changed and have more research conducted on the benefits of medical marijuana. Doug Distaso served his nation in the United States Air Force for 21 years. He had the opportunity to command joint aviation, maintenance, and support personnel globally and served as the primary legislative affairs lead for two U.S. Special Operations Command leaders. However, after an Air Force plane accident left Distaso with a traumatic brain injury, post-traumatic stress disorder (PTSD), and chronic pain, he was given more than a dozen prescription medications by doctors at the VA. "I was taking everything from opioids, antidepressants, benzodiazepines, and sleeping pills," Distaso stated. "Like countless other veterans, the cocktail of drugs that I was prescribed quickly threw my life into a turmoil, affecting my ability to perform at work, while straining my relationships at home." Distaso states that living his life in a prescription drug-induced, zombie-like state left his wife and family begging with him on Christmas morning to come back to them. "What brought me back to my family and career was medical cannabis. Cannabis helped me get off the pills and regain control of every facet of my life," Distaso said. Unfortunately, for millions of veterans who depend solely on their VA healthcare benefits, federal law ties their VA doctors' hands. It harshly denies these veterans access to needed medical cannabis as a treatment option. Distaso currently works for his fellow veterans as the Veterans Cannabis Project founder, which advocates for veterans' cannabis access, education to policymakers, and support for veterans seeking treatment options beyond the opiates and other prescriptive and addictive drugs they obtain from the VA. It is time for Congress to approve the VA to research the effects of cannabis on familiar veterans' health issues and allow doctors at the VA to recommend and assist veterans in accessing medical cannabis. The VA denial of cannabis Cannabis use is still branded as harmful to veterans on the VA's website. "Cannabis use for medical disorders is an issue of growing concern," the VA states. Cannabis also remains on the Schedule I list under the Controlled Substances Act, the same as heroin. According to the VA website, "measured studies have not been fully conducted to evaluate the safety or effectiveness of medical marijuana for PTSD. Thus, no proper evidence that marijuana is an effective treatment for PTSD has been collected." Conversely, the tide has turned nationally in terms of the attitude toward marijuana, especially for medicinal purposes. Despite the unattainability of medicinal marijuana at the VA, veterans nationally are using cannabis to deal with their PTSD symptoms of anxiety, depression, and chronic pain. Recent scientific studies are showing the medicinal properties of cannabis. The VA website downplays the approval of marijuana in the United States, stating that "several" states have accepted the use of medical marijuana and/or recreational marijuana. In all actuality, it's far more than "several." Thirty-three states have enacted medical marijuana laws that allow eligible people to obtain or grow cannabis to treat various conditions. Additionally, 15 states have decriminalized marijuana, and 11 states have legalized recreational marijuana. A recent poll conducted at Politico and Harvard's T.H. Chan School of Public Health shows that Americans feel that marijuana is much less harmful than alcohol, tobacco, or e-cigarettes. In the survey, one in five Americans state they believe marijuana is very harmful to people. Twice as many stated the same about alcohol, 52 percent characterized e-cigarettes as very toxic, and 80 percent indicated tobacco cigarettes are hazardous. And more than six in ten U.S. adults said they favor changing federal law to legalize marijuana for recreational use. Another recent survey shows strong majority support among Americans for legalizing marijuana. Also, almost all Democratic presidential candidates agree to remove marijuana from the federal list of controlled substances. And veterans and the American public overwhelmingly support medicinal cannabis for veterans. In the 2017 American Legion survey, 92 percent of veterans said they supported research into the use of medical cannabis, and 83 percent support legalizing medical cannabis. A new study on PTSD and cannabis A new study concludes that cannabis may already be helping Canadians cope with depression and suicide in people suffering from PTSD. This study was conducted on more than 24,000 Canadians, which concluded that people experiencing PTSD and not medicating with cannabis are far more likely to suffer from severe depression and have suicidal thoughts than those who used cannabis over the past year. The study provides initial evidence that cannabis use may contribute to decreasing the connection between PTSD, severe depressive, and suicidal states. This research states that there are limited treatment options for PTSD, so many patients have acted by medicating with cannabis to alleviate their symptoms. However, this is the first time that outcomes from a nationwide survey have exposed the potential benefits of treating the disorder with cannabis. This research documented the first relationships between PTSD, cannabis use, and severe mental health outcomes in the veteran population. The big question is: If a Canadian health survey looked at PTSD and cannabis with such a convincing conclusion, where is the VA on this issue, which affects as many as thirty percent of the American veterans who served in the wars since September 2001? Veterans group supports medical cannabis While the VA still stands on the statement that it is not allowed to do research; however, this is not actually true. They just have to coordinate with outside agencies to conduct it. Only one-third of veterans mentioned cannabis to their doctor because of the stigma attached to marijuana use. Veterans have a legitimate fear of reprisals at VA and in the workforce, where there have been programs that they can lose their jobs for testing positive for marijuana. We have found that in different parts of the country where the use of cannabis is less stigmatized open conversation can be conducted with the VA physicians. However, in parts of the country where it is still illegal, providers are more skeptical or judgmental. It shuts the veteran up and is then dangerous as the veterans do not communicate openly with their provider. Why the VA will not budge The biggest hurdle for veterans seeking cannabis from the VA is that it is still on that Schedule I list of controlled substances at the federal level. This means that cannabis "no acceptable medical use and has a more significant potential for abuse and risk for arrest," as identified by the federal government. The VA considers any form of marijuana illegal. This means veterans cannot get help accessing medical marijuana from their VA doctors, relying on their own means to obtain any. The recent congressional hearing explored bills that would allow for extended access to medical marijuana for veterans. VA representatives confirmed their position opposing any policies as long as marijuana remained illegal at the federal level. Many agencies are "committed to improving treatment options for veterans and supports research into potential treatment options that may prove valuable." Specific federal law restricts the VA's research with Schedule I controlled substances, including marijuana. Before conducting any VA research using a Schedule, I controlled substance would involve lengthy communications and coordination with the Drug Enforcement Administration (DEA), Food and Drug Administration (FDA), National Institutes of Health, National Institute on Drug Abuse, and the Health and Human Services. Particular requirements include reviewing an investigational new drug application and approval of the research protocol by the FD, obtaining the medical drug through NIDA and the nationally approved medical marijuana production laboratory, and an investigator registration and site licensure by the DEA. These restrictions that are contained in federal law are clear. Research is allowed but must be done with the identified federal entities. If Congress wants more federal research into Schedule I controlled substances such as marijuana, it can eliminate these restrictions. Multiple sources explain that Congress and the President can reschedule marijuana to make it accessible to veterans and make it researchable by the VA. Former VA secretary wants more research The Former VA secretary says that the VA should study cannabis. "It is a little bit strange that marijuana is Schedule I while cocaine is Schedule II," stated the former VA secretary. "To say there is completely no medicinal value or application in cannabinoids is not true at all." "There is already an FDA-approved drug on the market, which is a cannabinoid, to treat pediatric epilepsy." The FDA approved Epidiolex in June 2018; the first drug derived in the U.S. from the cannabis plant to reach local pharmacies. He added that when he ran the VA, he was told the agency could not discuss cannabis with veterans and could not do research. But he discovered later that this was not true. "We can talk to our veterans about it. We just cannot prescribe the cannabis," says the former VA Secretary. "It is possible to do research at the VA, but the barriers and bureaucracy are lengthy and painful. I can now more effectively articulate that Congress is the most likely player to streamline this research. And yes, it needs to be done." Medical marijuana research The Center for Medicinal Cannabis Research (CMCR) is the nation's oldest research center for the safety and efficacy of cannabis. CMCR recently announced research to explore the effectiveness and safety of medical cannabis as an alternative treatment for schizophrenia, insomnia, alcohol dependence, rheumatoid arthritis, and anxiety linked to anorexia. Research done by the CMCR has also shown that cannabis can be useful for relieving pain, but research has not been conducted for studying cannabis concerning PTSD. This center is directly linked to the VA's regional office located in San Diego. The legislation is not moving Certain Congress members have tried to push for new legislation to make medical marijuana available to veterans at the VA without success. Here are a few bills that have not made any progress: 1) The Veterans Equal Access Act allows the VA health providers to recommend medical marijuana to their veteran patients and provide the required paperwork to enroll in state marijuana programs. 2) The VA Medicinal Cannabis Research Act of 2018 supports the scientific and medical research of medicinal cannabis for veterans diagnosed with TBI, PTSD, chronic pain, and other injuries by clarifying that research of medicinal cannabis is within the authority of the VA. 3) The Veterans Medical Marijuana, Safe Harbor Act is an act that would enable VA physicians to issue medical cannabis recommendations under the laws of states where medical cannabis is legal. 4) The Safe Harbor Act would require the VA to conduct studies on the effects of medical marijuana on veterans in pain related to their treatment programs involving medical marijuana approved by states, veterans' access to these programs, and a reduction in veteran opioid abuse. OK, for dogs but not veterans? It is ridiculous that Americans in most states now have access to medicinal marijuana, but America's veterans do not. I have a non-veteran friend, and he receives medical marijuana for his dog's anxiety. He was shocked when he discovered that dogs could get medicinal marijuana, but veterans cannot get the same treatment at the VA. Washington, D.C. is an echo chamber of circular logic. We are convinced there is a national craving for this issue on medical cannabis for veterans. Still, politicians only seem to hear themselves and continue to assume that there is not. We must change this view and make it known. Cannabis May Help Veterans With PTSD After 17 years in the military and deploying to almost every terrorist filled location on Earth, former Green Beret Adam Smith discovered that while his combat battles had ended, his personal one still lingered. "I had a hard time with anxiety, sleeping, hyper-vigilance, and symptoms that revolve around PTSD," Smith, remembering his difficult transition to civilian life, starting in 2015. "I found myself hopeless and in an awful place," said Smith, who also suffers from the effects of several past brain injuries. "The bottom of this black hole was me sitting on a couch with a pistol in my mouth." Thankfully, Smith did not go through with it and said that in the years since, what's helped sustain him is the lessened joint pain, better sleep, and moderated his constant sensation of always feeling "switched-on," has been … self-medicating with cannabis. Smith is just the kind of veteran lawmaker that is trying to help with two U.S. House bills that approved at the House Committee of Veterans Affairs on March 12: H.R. 712, the VA Medicinal Cannabis Research Act of 2019, directing the Veterans Administration to research marijuana's impact on physical conditions related to active duty. H.R. 1647, the Veterans Equal Access Act of 2019, allows physicians to complete state-legal medical marijuana proposal paperwork due to VA doctors currently being prohibited from doing this, forcing veterans to turn to private-network physicians. Irritatingly Smith states, "When it comes to veterans and veterans' rights, the game of politics should not exist." Smith has publicly talked about his avoidance of Veterans Administration treatment because of its chosen response to suffering veterans. That response includes treating veterans' symptoms with anxiety meds, sleeping pills, and high blood pressure meds and does not necessarily treat the total patient. Smith finally realized in 2015 when he tried marijuana for the first time, alongside a military buddy who said marijuana had sharply reduced his seizures and improved his sleep. This may not display hard evidence to support cannabis as a solution for PTSD; many veterans swear by it. Post-traumatic stress is no joke; Post-traumatic stress is something that's hitting our community in an epidemic. The social answer to deal with the trauma is to drink and drug our way into distraction or sedation, so we do not have to feel the pain anymore. That should not be the methodology." Many Americans agree. A recent poll of 5,369 U.S. adults found support for CBD treatment, with 53 percent of those polled agreeing that medical dispensaries should be considered an "essential service." What seems here like a cultural shift may have as much to do with the current anxiety engendered by the coronavirus crisis (which has spiked cannabis sales) as it does the different sort of pain veterans and first responders experience. Marijuana is a top treatment for veterans' pain, PTSD, but the cost is a barrier According to recent survey data, military veterans are using cannabis to treat chronic pain, post-traumatic stress disorder, anxiety, and depression, among other ailments. But the cost of medical marijuana is a barrier since it is not covered by insurance, even though veterans are using cannabis as an alternative to pharmaceuticals. Final results from the 2019 Veterans Health and Medical Cannabis Study, which looked at 201 veterans in Massachusetts and 565 respondents nationwide, were presented at the Cannabis Advancement Series. The study, which was performed March 3 through Dec. 31, was conducted by Marion McNabb, Steven White, Stephen Mandile, and Ann Brum. Over half of the 201 Massachusetts veterans who completed the survey through outreach by veterans' groups, marijuana dispensaries, and social media sites were age 50 or older. Most, 54 percent had served in the Army. The sample was overwhelmingly male, 90 percent and 84 percent were white, non-Hispanic. Chronic pain, anxiety, and PTSD are the top medical conditions facing veterans. Nearly one in three, 30 percent, of the veteran participants, were currently or homeless in the past. Ninety-one percent of participants reported using medical marijuana. Recreational marijuana was used by 59 percent. Results from 2019 Veterans Health and Medical Cannabis Study Top health conditions Massachusetts veterans are facing As reported by 201 Massachusetts survey participants in the 2019 Veterans Health and Medical Cannabis Study 37% Chronic pain 25% PTSD 10% Anxiety Primary health conditions Massachusetts veterans find cannabis most helpful for treating 36% Chronic pain 24% PTSD 11% Anxiety 6% Depression Top barriers to accessing cannabis reported by Massachusetts veterans 55% Money to purchase prod money 37% Money required to get a medical card 33% Access to the right products 33% Stigma 26% Owning a firearm 21% Workplace testing or other policies Massachusetts veterans report cannabis allows them to: 89% Experience a much better quality of life 79% Experience much less psychological symptoms 69% Experience much less physical symptoms 44% Use alcohol much less now 40% Use prior medication (non-opioid) much less now 23% Use tobacco much less now 22% Use opioids much less now Many veterans responded to the survey reporting that cannabis provided relief for their primary medical troubles, and 77% said that they were actively trying to reduce the use of their over-the-counter or prescription medications with medical cannabis. The top symptoms being treated with medical cannabis included: pain, 51 percent; sleep problems, 50 percent; depression or mood, 45 percent; anxiety or panic attacks, 41 percent; and aggression, 24 percent. "It surprised me, but it is not that surprising," McNabb stated. "They are consumers of medical cannabis. They are finding relief in medical cannabis." The survey's findings brought additional attention to previously published research on medical marijuana by Staci Gruber. Gruber stated that almost all research on the impact of cannabis on the brain and cognitive functioning comes from recreational users, most of whom began using the drug as teenagers while their brains were still developing. Studies conducted by Gruber have found that after three months of treatment, medical marijuana patients demonstrated an improvement in task performance accompanied by changes in brain activation patterns measured in imaging. Further, after treatment, brain activation patterns appeared more similar to those in healthy controls, who weren't using marijuana than pretreatment with medical marijuana. Gruber said her research suggested that medical marijuana use may affect the brain differently compared to the brain impacts among recreational marijuana users. Consistent with the veterans' survey, Gruber's study also found medical marijuana patients reported improvements in how they felt and notably decreased their use of prescription drugs, predominantly opioid and benzodiazepines, after three months of treatment. Mandile became an advocate for medical marijuana after being seriously wounded in Iraq while deployed in 2005. His Veterans Affairs doctors put him on 57 medications, which included nine opioids. In 2013 he attempted suicide. In 2014, his wife's ultimate goal for Mandile was to wean himself from prescription drugs by using marijuana, which he accomplished in only five months. He formed a nonprofit organization called the Alternative Treatment for Veterans to advance awareness of medical marijuana and work with dispensaries to offer discounts to veterans who have been rated 100 percent disabled by the VA. The product 11 marijuana dispensaries across the state have picked up the product discounts testified on proposed legislation, H. 4274, that would allow veterans to use their VA paperwork to qualify for a medical marijuana card instead of paying hundreds of dollars for the state-required card. The 2017 state law legalizing the adult-use of marijuana called for the Cannabis Advisory Board to make recommendations to the Cannabis Control Commission on related costs associated with the purchase of medical marijuana by U.S. military veterans insured through the VA, and to make recommendations on improving cost-effective access. But the study and recommendations were never made by the Sept. 2018 deadline, Mandile said. "As much as legislators can feel the connection with anecdotal stories," Mandile said, "they needed something more concrete, more data-driven." This data found Massachusetts veterans spending an average of $79 a week on cannabis. Nearly three-quarters, 72 percent, purchase cannabis from regulated dispensaries, while one out of five, 19 percent, grow their money The money to purchase marijuana products and get a medical marijuana card was the top two topics reported in the veterans' survey. DAV - The Cannabis Cure DAV requests more research on medical cannabis as an alternative treatment for veterans with chronic pain, PTSD, and TBIs Like many veterans, military service rigors have taken a toll on Air Force veteran Jarid Watson's body. He is not sure when the injury occurred—perhaps during the 12 years of physical training or while loading and unloading cargo planes—but at some point, the ball joint of his hip tore his labrum and damaged the surrounding cartilage. The injury brought on Watson's chronic pain and eventually led to his medical retirement in 2016. It also severely affected his sleep, which negatively influenced his motivation and mood. As a father, husband, student, and entrepreneur, something had to be done to fight this pain and restore being able to achieve a good night's rest to restore himself, his family, career, and studies. For Watson, there was only one choice. "As soon as I knew my military career was ending and dealing with this chronic pain was in my future, I considered medical cannabis as an option because I'm not going to take pain pills and potentially get addicted.' Watson's reluctance toward pain pills stems from his personal experience. As a native of northeast Ohio, the Afghanistan War veteran lost two close friends to opioid overdoses and has witnessed how addiction can destroy individuals and their families. "That area has been devastated with opiate and heroin use. That is tearing families apart in this country. It is killing people," Watson said. The National Center for Health Statistics released a report in 2017 stating that there was a national opioid crisis killing more than 42,000 Americans in 2016. Alarmingly, a 2013 analysis by the Center for Investigative Reporting found that opioid prescriptions for veterans spiked 270 percent over 12 years, while a 2011 Department of Veterans Affairs study found that veterans were twice as likely to die as compared to the rest of the population from an opioid overdose. The VA also estimates that 68,000 veterans, 13 % of the total veteran population currently taking opioids, have an opioid-use disorder. According to VA officials, doctors continue to prescribe them for chronic pain, a condition that 60 percent of veterans sustained from deployments to the Middle East and 50 percent of older veterans. "Sixty percent of what the VA treats falls into the category of chronic pain, and the VA system is not designed to do much more than push pills, and those pills are not working," said Nick Etten, founder and executive director of Veterans Cannabis Project. The story of Air Force veterans Jarid and Priscilla Watson helps display the effectiveness of medical cannabis. Jarid uses medical cannabis to help treat his chronic hip pain rather than using opioids pharmaceuticals, which he feels are dangerous. "He's much happier, more productive, and more motivated in his everyday life," said Priscilla, noting the difference. Etten, a former Navy SEAL, also noted that medicinal cannabis is an effective treatment for the wounds he sustained in the Middle East—PTSD and TBI. He named pain, sleep, and anxiety as the primary symptoms veterans deal with concerning their service-connected injuries. "Cannabis is proving to be safe and effective in treating my injuries," he said. "That's where it can be transformative and a potential game-changer." "Before cannabis, he was constantly complaining about how tense he was and how much pain he had," said Watson's wife, Priscilla. "His pain would keep him up all night, so he would be exhausted, tired, and need naps throughout the next day. But now, he sleeps all night and is not in pain anymore." As an Air Force veteran and nutritional therapist herself, Priscilla feels cannabis is a more natural and safer alternative to attending to his pain than opioid pharmaceuticals, noting the disparity between what she calls "the obsolete argument that marijuana is dangerous." "He is happier, more productive, and more motivated," she added. "So, it has changed his quality of life greatly." Medical cannabis's benefits associate with its responsible use, including refraining from driving while under the influence and ensuring that proper dosage is administered. "As someone with a nutrition background, I do not let Jarid smoke it because I do not like having to deal with the damaging effects of the smoke in the lungs," she said. "He uses cannabis in the form of edibles, which I think is a lot safer, and tends to produce a more positive effect." While the VA cannot deny any veterans benefits due to medical marijuana use, the VA providers cannot recommend or prescribe any form of cannabis since the Food and Drug Administration still classifies it as a Schedule I drug. Instead, Veterans must pay out of pocket for an annual physician's evaluation and medical cannabis cards in one of 30 states, which have legalized medical marijuana. Participation in any state marijuana program does not affect a veteran's eligibility for VA care and services. VA providers can discuss cannabis use with veteran patients and adjust care and treatment plans as needed. However, Etten adds that the federal classification of cannabis leaves many veterans in limbo. While some can afford to pay the out-of-pocket costs, many others cannot and must rely solely on the VA for health care. Until cannabis has been removed from the Schedule I list and elevated from a health policy issue where it can be treated as a medical treatment, we will be stuck in this legal gray zone where we are currently located. However, the federal government maintains that more research into the efficacy of medical marijuana needs to be conducted before it is declassified and made available to service-connected disabled veterans through the VA. DAV Resolution #23 supports additional research in the use of medical cannabis, noting the DAV's call for more research—rather than just legalization—requiring the need to know more about both the potential benefits and risks associated with medical marijuana. As veterans, we do not want to prescribe a new form of treatment without research showing it is safe and effective. The VA Medicinal Cannabis Research Act of 2018 promotes the scientific and medical research into the safety and efficiency of medicinal cannabis usage on veterans diagnosed with PTSD, TBI, chronic pain, and other injuries by clarifying that research medicinal cannabis is well under the authority of the VA. "We have heard of veterans who use cannabis medicinally to cope with physical and mental injuries sustained from active service for our country," said Walz. "Twenty-two percent report using cannabis as a safer and more effective alternative to opioids and drug cocktails currently prescribed by VA for the medical conditions such as PTSD or chronic pain." "As a physician, I am acutely aware of the need to look for opioid alternatives to treat patients' chronic pain," said Roe. "I've heard from many veterans who suffer from physical and invisible wounds and believe medical cannabis could benefit them." The Veterans Medical Marijuana Safe Harbor Act (S. 3409) would also empower VA physicians to issue medical cannabis recommendations under states' laws where it is legal. This legislation would also force the VA to conduct studies on "the effects of medical marijuana on veterans in PTSD and pain" and "the relationship between treatment programs involving medical marijuana that are approved by States and a reduction in opioid abuse among veterans." In 2014 a study by the Journal of the American Medical Association discovered that medical marijuana laws had a twenty-five percent lower average annual opioid overdose death rate than states without such laws. "If veterans can ease some of their chronic pain, symptoms of injuries they have received from serving their country without turning to opioids, the VA has a responsibility to research it," said Sen. Jon Tester. Despite the criticisms of medical cannabis use, as it becomes gradually accepted, no other demographic stands to benefit more from its use and legality as America's veterans. "I was tentative at first to be open about it because of the stigma that is still associated with cannabis," said Watson. "However, ultimately, you finally realize how much it helps, and you feel guilty for not sharing that information with everyone else." Veterans organizations like DAV are precisely what medical cannabis users need to advocate for making medical cannabis an available alternative for veterans everywhere. References: Bonn-Miller, M. & Rousseau, G. (2015). Marijuana Use and PTSD Among Veterans. Department of Veteran Affairs. Retrieved from https://www.ptsd.va.gov/professional/treat/cooccurring/marijuana_ptsd_vets.asp Hunter, T. (2018). A Cannabis Cure. Disabled American Veterans (DAV). Retrieved from by https://www.dav.org/learn-more/news/2018/the-cannabis-cure/ Oleck, J. (2020). Cannabis May Help Veterans With PTSD. And Lawmakers May Be Acknowledging That. Forbes. Retrieved from https://www.forbes.com/sites/joanoleck/2020/03/30/cannabis-may-help-veterans-with-ptsd-and-lawmakers-may-be-acknowledging-that/?sh=79ecf8315fe6 Reno, J. (2019). People in 33 States Can Use Medical Marijuana. Why Can't Veterans Get It for PTSD? Healthline. Retrieved from https://www.healthline.com/health-news/why-are-veterans-still-being-denied-cannabis-for-ptsd-treatment Spenser, S. (2020). Marijuana is a top treatment for veterans' pain, PTSD, but the cost is a barrier. The Metro West Daily News. Retrieved from https://www.metrowestdailynews.com/news/20200204/marijuana-is-top-treatment-for-veterans-pain-ptsd-but-cost-is-barrier

La planta de cannabis contiene varios cannabinoides, cada uno con sus propios beneficios y efectos, y el cannabidiol (CBD) es uno de los cannabinoides más populares del mercado. Sin embargo, todavía hay muchos conceptos erróneos sobre el CBD rondando por ahí. En este episodio, hablaremos sobre los mitos comunes acerca del CBD.El CBD es uno de los cannabinoides más investigados dentro de la planta, por que lo que existe mucha información, pero falta de precisión, en general, sobre el cannabis. Estos son algunos de los conceptos erróneos más comunes sobre el CBD, explicados:El CBD no se ha investigado lo suficiente para determinar sus verdaderos beneficios, por eso, cuando se les pregunta sobre el cannabinoide, muchos expertos en salud afirman que nunca se ha demostrado realmente que el CBD ayude con las condiciones de salud. Aunque ciertamente queda por hacer más investigación, es falso afirmar que no hay absolutamente ninguna prueba de que los cannabinoides ayudan a las condiciones de salud. La existencia de Epidiolex es prueba suficiente de que el CBD ha sido bien investigado dentro de la comunidad médica. Este medicamento es el primer producto de CBD aprobado por la FDA, debido a su éxito en el manejo de las convulsiones para quienes padecen epilepsia, explica el sitio web Green Flower.El aceite de CBD y el aceite de semilla de cáñamo son lo mismo. Dado que el CBD y el cáñamo carecen de las intensas propiedades psicoactivas del THC, muchas personas creen que los dos productos son similares. Sin embargo, esto no es cierto.El CBD es un cannabinoide derivado de la planta de cannabis. Si bien se puede extraer de las hojas de la planta de cáñamo, el aceite de semilla de cáñamo se elabora exclusivamente a partir de semillas de cáñamo y las semillas en si no contienen CBD. Por lo tanto, el aceite de CBD puede contener algunas propiedades de la planta de cáñamo, pero el aceite de semilla de cáñamo no contendrá CBD ni ninguno de sus efectos reconocidos.Los aceites también tendrán diferentes efectos y servirán para diferentes usos para el consumidor: el aceite de semilla de cáñamo se utiliza más comúnmente para el cuidado de la piel, mientras que el aceite de CBD se usa en un sentido más terapéutico, como para controlar el dolor, la ansiedad o la depresión.El CBD afecta a todos de la misma manera. Si bien es posible que los beneficios y efectos del CBD no sean demasiado variados, esto no significa que el cannabinoide afectará a todos los consumidores de la misma manera. La forma en que le afecta el CBD depende completamente de su composición genética, su estado de salud actual y su sistema endocannabinoide. Dado que este cannabinoide ofrece múltiples beneficios, diferentes consumidores pueden recurrir al CBD por muchas razones diferentes, ya sea depresión, dolor crónico, inflamación o epilepsia.El CBD es 100% no psicoactivo. Aunque el CBD no es tan psicoactivo como el THC, que es responsable de la "euforia" que sentimos cuando consumimos, no es exacto decir que el CBD es completamente no psicoactivo.El cannabinoide aún interactúa con el sistema endocannabinoide de tu cuerpo y tu cerebro, y puede tener efectos alteradores en su estado de ánimo. Por ejemplo, si utilizas CBD para controlar su ansiedad o aumentar la felicidad, esos cambios en las señales de serotonina ya han afectado tu cerebro y tu estado mental en general, afortunadamente estos efectos son para bien.El CBD es adictivo. Uno de los conceptos erróneos más comunes sobre el CBD y el cannabis en su conjunto es que es adictivo. Sin embargo, la investigación ha encontrado lo contrario, y muchos pacientes de cannabis medicinal utilizan la planta para recuperarse de otras adicciones, como el alcohol o la heroína.Ahora que hemos hablado de algunos conceptos erróneos más comunes en torno al CBD, mencionemos algunos de los hechos que rodean al cannabinoide y los beneficios que los consumidores tienden a obtener del uso de CBD.El CBD puede ayudar a aliviar el dolor. Uno de los beneficios más comúnmente reconocidos del CBD es su potencial para aliviar el dolor. Al interactuar con el sistema endocannabinoide del cuerpo, el CBD reduce la inflamación, lo que tiene un efecto positivo en cualquier persona que sufra de dolor crónico o molestias. Esto podría ser particularmente beneficioso para cualquier persona que padezca enfermedades dolorosas como artritis o esclerosis múltiple.El CBD puede ayudar a reducir el acné. El CBD es excelente para el cuerpo en general, por dentro y por fuera, y muchas personas que padecen enfermedades de la piel utilizan el cannabinoide como una forma de aliviar los síntomas. Debido a sus propiedades antiinflamatorias, el CBD también ha demostrado ser exitoso para controlar los brotes de acné. Esto es particularmente beneficioso para cualquier persona que padezca afecciones cutáneas graves como eczema o psoriasis.El CBD puede ayudar a mejorar la salud del corazón. La lucha del CBD contra la inflamación es beneficiosa para el cuerpo de varias maneras, incluido el corazón. Se ha reconocido que el CBD reduce los latidos cardíacos irregulares y reduce la presión arterial, lo que puede contribuir a la salud general del corazón.Dado que el CBD también es reconocido por reducir la ansiedad y/o la depresión, esto también puede contribuir a los efectos de alivio general sobre el corazón.

Follow Kirstyn on Instagram! @kirstyn_blaked Follow her photography account! @kirstynblakephoto In this episode, Lindsey chats with her new Cannabombz assistant, Kirstyn! They discuss life as cannamoms, Kirstyn's struggle to leave her strict home state of Iowa with her twins due to a paraphernalia charge, why she uses cannabis, traveling with cannabis, and more. Thanks for listening! New episodes every Sunday. Cannabis legality in Iowa is discussed. Here's information on the laws and penalties: https://norml.org/laws/iowa-penalties-2/   1:20 Kirstyn talks about how she introduced her twins to Cannabis through a video that showed how it helped a baby struggling with seizures. There is now an FDA-approved treatment called Epidiolex- a plant-based formulation of CBD- used to treat seizures. Learn more about how cannabis is being used and studied to treat epilepsy: https://www.epilepsy.com/learn/treating-seizures-and-epilepsy/other-treatment-approaches/medical-marijuana-and-epilepsy 14:00 Lindsey and Kirstyn chat about bringing Cannabis along on their domestic flights. Keep in mind that this is their personal experience, they are not recommending anyone to do so, and flying with cannabis is unfortunately still illegal. Do so at your own risk. 14:58 Kirstyn mentions having her palms wiped in the airport. From what the TSA has shared, this is actually not to detect drugs but to collect explosives residue for testing. Often times, this is simply a random test, or may be performed due to the detection of glycerine- an ingredient sometimes found in soaps and lotions.

We pre-recorded today's conversation via Zoom with neurologist and epileptologist, Dr. Paul Lyons. Dr. Lyons is the medical director of the Virginia Comprehensive Epilepsy Program at Winchester Medical Center, an NAEC Level 4 epilepsy center. [The National Association of Epilepsy Centers (NAEC) accredits epilepsy centers and recognizes four levels of care. Level 4 centers are the highest level centers, offering the most “complex forms of intensive neurodiagnostic monitoring, as well as more extensive medical, neuropsychological, and psychosocial treatment. Level 4 centers also offer a complete evaluation for epilepsy surgery, including intracranial electrodes and a broad range of surgical procedures for epilepsy.”] The Virginia Comprehensive Epilepsy Program at Winchester Medical Center is an NAEC Level 4 adult and pediatric epilepsy center. It is one of only three centers in Virginia to offer level 4 epilepsy care for both children and adults. The program is a collaboration between Winchester Medical Center and two Winchester-based physician practices, Winchester Neurological Consultants (neurology practice) and Virginia Brain and Spine Center | Valley Health (neurosurgery practice). The founders of the program, epileptologist Paul Lyons, MD (Winchester Neurological Consultants) and neurosurgeon Lee Selznick, MD (Virginia Brain and Spine Center | Valley Health) envisioned integrated services for the treatment of epilepsy and pursued a cohesive, comprehensive program for our region. Dr. Lyons defined Epilepsy, explained the role seizures play in diagnosis and talked about how an FDA approved pharmaceutical grade cannabinoid extract called Epidiolex is changing how several severe seizure disorders are being treated, and the dramatic impact it is having on patients' lives locally. Beginning in 2015, Dr. Lyons, The Virginia Comprehensive Epilepsy Program at Winchester Medical Center and the Valley Health Clinical Research department were involved in a series of clinical research trials studying the efficacy of Epidiolex in the treatment of two severe forms of epilepsy; Lennox-Gastaut syndrome (LGS), and Dravet Syndrome. Children and adults with each type of epilepsy were recruited for participation in the controlled trials. For one of the studies, the Virginia Comprehensive Epilepsy Program at WMC was the highest enrolling site in the country. Most recently, in August of 2020, the U.S. Food and Drug Administration (FDA) approved EPIDIOLEX® (cannabidiol) oral solution to treat seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older. TSC is a rare disease that causes benign tumors to grow in vital organs of the body and is a leading cause of genetic epilepsy. Although tuberous sclerosis complex is a rare condition, Winchester Neurological Consultants currently sees a number of adult and pediatric patients with TSC. Along with this new indication, the age range has been expanded to include patients one year of age and older who experience seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome. EPIDIOLEX, the first plant-derived cannabinoid prescription medicine and the only FDA-approved form of cannabidiol (CBD), was initially approved by the FDA in June 2018 for the treatment of seizures associated with LGS or Dravet syndrome in patients two years of age and older.

On April 6th, the DEA announced that Epidiolex, the first Cannabis-formulated drug to be approved by the FDA in 2018, was being removed from the Controlled Substances List. Bob and Eric discuss the significance of this development, and whether it will spur more cannabinoid-based drugs to be developed by pharmaceutical companies. They also address which cannabusinesses are eligible and which are ineligible for financial assistance through the federal stimulus package. Hoban Law Group created The Hoban Minute to get closer to our network, highlight the many voices that make up this multifaceted global industry and provide a broader perspective on cannabis, hemp, and marijuana international markets.  Contact Hoban Law Group for all your cannabusiness legal needs.

About Anna Symonds Anna has been in the cannabis industry for four years and is the Director of Education for East Fork Cultivars. For East Fork, Anna developed CBD Certified, a free cannabis science educational program which she has presented for the staff of more than 100 dispensaries across Oregon, as well as for numerous other retailers, industry groups, and the general public. This initiative has directly educated 2500+ people about CBD and cannabis science, and now will reach many more as an online class and on public access TV.  Anna holds an MA in Communication and is a member of the International Cannabinoid Research Society. She continues to educate lawmakers at the local, state, and national levels, lobbying for cannabis legalization, patient access, and removing the barriers to clinical research.    As an Athlete Ambassador for the nonprofit Athletes for Care, Anna speaks widely about the therapeutic benefits of cannabis for elite athletes and everyday people, and promoting normalization of the plant. She spearheaded a petition signed by more than 150 professional athletes asking the World Anti-Doping Agency (WADA) to remove THC from its Prohibited Substances list, receiving national and international news coverage.   ------------------- Episode Notes 3:00 Anna's journey into the cannabis industry 5:00 CBD Myths 5:30 Is "Psychoactive" the appropriate term for CBD? 7:20 How does CBD work in our body? 9:45 The medical marvel of the placebo effect 14:45 The Endocannabinoid System (ECS) 17:00 The Entourage Effect 18:20 Cannabis and social justice. How cannabis companies can do what's right 22:45 The Last Prisoner Project 25:00 Knowledge disparity with consumers and the business community 29:00 What is Rugby? 33:00 Cannabis and athletics, Cannabis for Care 36:00 Inflammation in the human body 38:30 How Anna uses cannabis and hemp to care for her body 39:30 What cannabis companies need to do to appeal to athletes 43:00 How consumers should know which hemp and cannabis products to purchase 46:00 Full spectrum vs isolate CBD 53:45 Hemp seed oil vs CBD oil 59:30 How an individual can begin to dose CBD oil 1:02:00 What is the titration effect? 1:06:00 Where to find sources for CBD and cannabis education 1:08:00 New study doubting Epidiolex; Anna's thoughts 1:12:00 How to contact Anna   ------- About Spectrum Labs At Spectrum Labs, we source local hemp and extract high-quality Full Spectrum Hemp extracts that even our families can use. Spectrum Labs can manufacture these full-spectrum hemp extracts: *Crude *Distillate *Isolate *Tinctures *Vapes *Gummies *Lotions *Candies *Custom formulations To learn more about Spectrum Labs, visit www.TheSpectrumLabs.com or contact us at (828) 229-7952 Asheville, NC --- ***If you enjoy the podcast, please consider leaving a short review on Apple Podcasts/iTunes. It takes less than a minute, and it really makes a difference in helping Apple recommend the show to new listeners. I also love reading the reviews!

Epidolex CBD - Friend or Foe? You Decide. Written By Mike Robinson ~ Cannabis Heals Cancer Survivor ~ International Cannabinoid Cancer Research Institutes/Domestic Animal Research Ctr. Co-Founder/Director We all knew the pharmaceutical industry would step into the world of Medicinal Cannabis and take over with a bang, but we did not expect it to happen with a whirlwind of professionals voicing concerns globally. Questions are looming about dosing, increased seizures in patients, a death in the trials to seizures, and even other epilepsy drugs that combined with this one can be life-threatening. Even the likes of Professor Raphael Mechoulam, the Israeli organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel who first isolated and identified THC in the 1960's and discovered the Endocannabinoid System 3 decades later, created panels and meeting from across the Atlantic to here in California this coming week, and will address this at the huge CannX conference he hosts every year in his country. Dr. David Bearman of the American Academy of Cannabinoid Medicine has been invited to give his input there. Liz Minda, cannabis advocate and nurse, the mother of Jadyn with Severe Intractable Epilepsy stated, "Epidiolex was the last pharmaceutical we tried and it failed for seizure cessation. Full spectrum cannabis oil stopped seizures and gave her a brighter cognitive and physical ability every day. The best Leap of Faith I have ever taken. Currently, for the last 12 months Jadyn is on CBD only, not Epidiolex!" I was part of her compassion crew that helped wean Jadyn from GW's CBD to the plant - and it's nowhere near the same. It seems that many are quite upset at the fact that Pharmaceutical CBD will be compared to Hemp derived and Cannabis Flower derived CBD products that do not cause the problems nor carry side effect warnings such as GW Pharmaceuticals has been forced to put on it's product by the F.D.A., take a look - you decide. Would you take this drug as a replacement for pharmaceuticals? Would you consider it a 'good representation' of the 'dangers' of Cannabis products? How many of us want these type of warnings blasted out on TV advertisements for the drug creating a new "Reefer Madness 2019" in which people that are considering cannabis as medicine will then change their mind. Approval of a drug, or a way to scare consumers away? WARNINGS AND PRECAUTIONS (From FDA Website) Hepatocellular Injury: EPIDIOLEX can cause transaminase elevations. (LIVER DAMAGE) Concomitant use of valproate and higher doses of EPIDIOLEX increase the risk of transaminase elevations. See Full Prescribing Information for serum transaminase and bilirubin monitoring recommendations. (5.1)  Somnolence and Sedation: Monitor for somnolence and sedation and advise patients not to drive or operate machinery until they have gained sufficient experience on EPIDIOLEX. (5.2) Suicidal Behavior and Ideation: Monitor patients for suicidal behavior and thoughts. (5.3) Hypersenstivity Reactions: Advise patients to seek immediate medical care.(5.4) Withdrawal of Antiepileptic Drugs: EPIDIOLEX should be gradually withdrawn to minimize the risk of increased seizure frequency and status epilepticus. LET ME INTERRUPT: Status epilepticus (which kills nearly 50,000 people per year, Olympian "FloJo" died of seizures/status in her sleep) is caused by discontinuing a cannabis product? Since when does stopping a cannabis created product CAUSE the problem you're treating? Since when is CBD addictive? Never... but when does a pharmaceutical cause us problems? When are they addictive? Daily. (5.5) ADVERSE REACTIONS: The most common adverse reactions (10% or more for EPIDIOLEX and greater than placebo) are: somnolence; decreased appetite; diarrhea; transaminase elevations; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder, and poor quality sleep; and infections. (6.1). (ALL of the above will be 'disclaimed' in Television and print advertisements, and quickly the world will liken CBD itself to Big Pharma's version) USE IN SPECIFIC POPULATIONS: Pregnancy: Based on animal data, may cause fetal harm. I'm not sure how you're deciding on this one but for me this is quite obvious. It's not CBD that does these things to people, it's pharmaceuticals. It's not the plant that would ever cause these problems - it's pharmaceuticals. Leave it to that industry to dirty the name of a plant that saves and changes lives daily. We as a movement to legalize nature should not step back and watch, once again, as Big Pharma creates a cannabis medicine and it's scheduled way down the list like Marinol (Synthetic THC) which has been a Schedule 3 since 1985. Epidolex proposal is at Schedule 4.   How possibly can our country's leadership sleep at night with the plant these drugs came from still schedule 1 while our citizens fight death defying illness and fight to gain access to a plant to become "Illegally Healed"? Guest Bio and Social Media Links: Mike Robinson, the Director of Communications for The American Academy of Cannabinoid Medicine, is a Multiple Cancer survivor that's used cannabis oils extensively as well for Severe epilepsy, Chronic Lyme Disease, PTSD, and in pain management. Over the last 5 years Mike has shared his journey and analytics on cannabinoid medicine research globally while assisting patients and clinicians during his own journey. The co-founder and Director of the International Cannabinoid Cancer Research Institutes, joined by some of the top research doctors and experts across the globe, Robinson brings vision to the future of Cannabis as Medicine. As well, he's founded The Domestic Animal Research Center that focuses on Cannabinoid Medicine for all vertebrates, including livestock and zoo animals.   An extensive background includes being an effective leader of a large Cannabis compassion program providing to the disadvantaged that treated countless medicinal cannabis consumers with various alternative protocol treatments, Robinson is also a published journalist and research analyst. Historically a former Registered Ca. State Lobbyist 1997 and Pro-bono non-attorney representative for children with disabilities nationwide for over 2 decades, a former member of the Board of Directors for Big Brothers and Sisters, the founder and board member of multiple nonprofits that advocate/advocated for the rights of disabled children, and most important, the Dad of one of his former compassion patients that he's taken on as his own daughter. https://www.mikesmedicines.com/medical-marijuana/the-cannabis-lovestory/ Mike Robinson Linkedin   Credits: Producer: Barry Krauss Sponsor: Soil to the Oil Advisory and Media Podcast Links: CLICK HERE TO SUBSCRIBE ON ITUNES AND LEAVE A REVIEW! Click Here For Podcast Website Join and Like our Facebook Page!

CBD - Epidiolex For Epilepsy and Brain InjuryDr. Michael D. Lewis is an expert on nutritional and holistic interventions for brain health, particularly the use of omega-3 fatty acids and https://www.medicalnewstoday.com/articles/317221.php (CBD Oil) for the prevention, management, and rehabilitation of concussions and traumatic brain injury (TBI). In this CBJ Episode, he discusses a new product, Epidiolex, which uses CBD Oil for epilepsy and brain injury. See the references below for more specific research information about FDA approval. He founded the Brain Health Education and Research Institute in late 2011 upon retiring as a Colonel after a distinguished thirty-one-year career in the US Army. His remarks are researched, informed and delivered from the voice of experience. Ed Note: This is his third [previous CBJ posts on Concussions/TBI: http://corebrainjournal.com/171 (CBJ/171, ) http://corebrainjournal.com/224 (CBJ/224)http://corebrainjournal.com/171 (]) interesting interview here that discusses medical details of CBD oil applications for multiple levels of brain and body recovery. Photo by https://unsplash.com/photos/xZqr8WtYEJ0?utm_source=unsplash&utm_medium=referral&utm_content=creditCopyText (Joshua Sortino) on https://unsplash.com/collections/975037/the-path?utm_source=unsplash&utm_medium=referral&utm_content=creditCopyText (Unsplash) Dr. Lewis' Brain-Focused BioIn late 2011 upon retiring as a Colonel after a distinguished thirty-one-year career in the US Army. His pioneering work in the military and since has helped thousands of people around the world and is regularly featured in the media, including CNN's Sanjay Gupta, MD, show and numerous radio shows and podcasts. A graduate of the US Military Academy at West Point and Tulane University School of Medicine, Dr. Lewis is board-certified and a fellow of the American Colleges of Preventive Medicine and Nutrition. He completed postgraduate training at Walter Reed Army Medical Center, Johns Hopkins University, and the Walter Reed Army Institute of Research. He is currently in private practice in Potomac, Maryland (BrainCARE, http://www.BrainCARE.center (www.BrainCARE.center)); is a consultant to the US Army and Navy as well as several organizations, institutes, and nutrition companies around the world; and is a founding member of the Pop Warner Youth Football Medical Advisory Board. ----------- [spp-tweet tweet="#Concussion #CTE #TBI #treatment now understood through a new #CBDOil Product #Epidiolex approved by the FDA Details http://corebrainjournal.com/250"] ------------ Treatment Links and References, Amended 8-28-18His Book: When Brains Collide: http://geni.us/mlewis (What Every Athlete and Parent Should Know About the Prevention and Treatment of Concussions and Head Injuries): Michael D. Lewis MD - Global Amazon Link https://www.greenwichbiosciences.com/products-pipeline/research-trials/ (Greenwich Biosciences - Epidiolex Physician Clinical Program) - Indications & Research Additional bonus: Dr. Lewis CBD Oil Discount for CBJ Listeners: 15% discount at http://pluscbdoil.com (PlusCBDOil.com) - use the discount code: radio2017 - No Time Limit on this offer. See this excellent series of https://www.cnn.com/2018/02/14/health/concussion-blood-test-fda-bn/index.html (Video Explanations on CTE at CNN) - with a discussion of this testing. https://www.banyanbio.com/ ( Banyan Biomarkers Testing) - The concussion test is discussed at http://corebrainjournal.com/224 (CBJ/224.) Dr. Lewis' Website: http://www.brainhealtheducation.org (www.brainhealtheducation.org) with deeper details and downloads on the Omega-3 recommendations discussed briefly in this and his other interviews. His BrainCARE Center: http://www.BrainCARE.center (www.BrainCARE.center) Dosing & Research: https://www.projectcbd.org/science/cannabis-dosing/cannabis-dosing-101...

Help support the show! - http://www.patreon.com/dailyinternet   Merchandise! - https://teespring.com/stores/the-ireadit-emporium   #5 - Transport Canada investigating feces falling from sky   #4 - Human Blood Cells have been transformed into functional neurons   #3 - Texas GOP endorses Marijuana Decriminalization   #2 - Senator Lucy Gichuhi says $200,000 salary is 'not a lot of money'   #1 - Cannabidiol, or CBD, is a marijuana compound linked to a range of potential health benefits but does not get you high. The roughly $1 billion CBD industry is slated to shift into high gear if the federal government approves the first CBD-based drug, an epilepsy medication called Epidiolex.   Nathan -   Schwahn -       Connect with us:   Patreon: http://www.patreon.com/dailyinternet   Website: http://mjolnir.media/ireadit Subreddit: http://www.reddit.com/r/ireaditcast   Facebook: http://www.facebook.com/ireadit YouTube: https://www.youtube.com/channel/UCZXcQHg5RGMinTm5_yLOGVg   Instagram: https://instagram.com/ireaditcast Twitter: http://twitter.com/ireaditcast   E-mail: feedback.ireadit@gmail.com Voicemail: (508)-738-2278   Michael Schwahn: @schwahnmichael Nathan Wood: @bimmenstein